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INTRODUCTION 
Medical devices are critical in modern-day medical practice. At the 
same time, they are major contributors to morbidity, mortality and costs for 
health care delivery. The use of a medical device is the greatest exogenous 
predictor of healthcare-associated infection.[1]Most nosocomial infections 
occur at 4 major body sites - the urinary tract, respiratory tract, bloodstream, 
and surgical wound sites.The use of a medical device causes a breach in the 
natural defence mechanism. In fact, 95% of hospital acquired urinary tract 
infections are associated with a urinary catheter, 86% of hospital acquired 
pneumonias are associated with mechanical ventilation, and 87% of hospital 
acquired bloodstream infections are associated with an intravascular 
device.[2]The last type, catheter-related bloodstream infection (CRBSI) is the 
most life threatening and is associated with significant medical costs.[4] 
Eventhough the Central Venous Catheters provide necessary vascular access, 
they predispose patients for a spectrum of infections ranging from local site 
infection to blood stream infections and also lead to metastatic seeding of 
infections in other organs.[3] 
Central Venous Catheters are used [5] 
· for the administration of fluids 
· medications 
· parenteral nutrition 
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· blood products 
· to monitor hemodynamic status 
· to provide hemodialysis 
Microorganisms introduced into the CVC can be [6] 
· from the skin of the patient at the catheter insertion site 
· from a contaminated catheter hub(health care worker hands) 
· from hematogenous seeding of the device  
· from infusion of contaminated infusate 
Micro-organisms commonly attach to the medical devices and form 
biofilms that lead to colonization and sometimes infection. Biofilms are sessile 
microbial communities in which the organisms produce an extracellular 
polymeric substance (EPS) matrix.[10]About 65% of Hospital-acquired 
infections are caused by biofilm formation.[8]The process of biofilm formation 
is complex and in the case of central venous catheters, depends on multiple 
factors, such as the 
· characteristics of the catheter material 
· presence of a conditioning film 
· hydrodynamics 
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· physical and chemical properties of the liquid in contact with the 
catheter surface 
· properties of the microbial cells [7]. 
  It has been reported that biofilms may form within 3 days after catheter 
insertion .[10] Biofilm formation is more predominant on the external surface of 
catheters in place for 10 days; however, with increasing catheter duration (>30 
days), biofilm formation in the catheter lumen tends to predominate [7]. 
Biofilm organisms may elicit disease processes by  
· detachment of individual cells or aggregates of cells from the device 
surface 
· by production of endotoxins or other pyrogenic substances 
· biofilms may provide a niche for the development of antimicrobial-
resistant organisms by means of failure of antibiotic penetration, slow 
growing state in the biofilms causing reduced susceptibility and by 
means of different gene expressions in the planktonic and sessile 
counterparts.It has also been suggested that the negatively charged 
exopolysaccharide is very effective in protecting bacterial cells from 
cationic antibiotics by restricting their permeation.[8] 
Gram-negative bacteria, Gram-positive bacteria and yeasts can form 
biofilms . The most common biofilm-forming bacteria include Enterococcus 
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faecalis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus 
viridians, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and 
Pseudomonas aeruginosa. [9]  Biofilms may be composed of a single species 
or multiple species, depending on the device and its duration of use in the 
patient. Thus the biofilm matrix may act as a filter, entrapping minerals or 
host-produced serum components and becomes tenacious.[10] 
Catheter-related infections will continue to pose a serious threat unless 
prevention strategies, diagnostic techniques, and treatment modalities are 
implemented to address the pathogenic mechanisms of CRBSI and the 
microbiology of biofilms associated with vascular access devices.[11] 
  Hence keeping this view in mind, the present study is designed to detect 
the presence of central venous catheter associated blood stream infections 
caused by various bacteria, their ability to form biofilms and their 
susceptibility patterns to various antimicrobial agents in order to provide 
effective antibiotic strategy to reduce the incidence of hospital acquired blood 
stream infections.    
  
 
AIMS & OBJECTIVES 
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AIMS AND OBJECTIVES 
 To isolate and identify the bacterial and fungal organisms causing 
central venous catheter related blood stream infection. 
 To analyse the biofilm forming potential of the organisms isolated. 
 To study about antimicrobial susceptibility pattern of the isolates and to 
correlate the antimicrobial resistance with the biofilm formation 
 
  
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
Definitions 
Healthcare-associated infection(HAI)[1] – An infection acquired in the 
hospital by a patient who was admitted for a reason other than the infection. 
An infection occurring in a patient in a hospital or other health care facility in 
whom the infection was neither present nor incubating at the time of 
admission. This includes infections acquired in the hospital but appearing after 
discharge and also occupational infections among staff of the facility. 
Blood Stream Infection(BSI)[8] – two major categories of Blood 
stream infections are  
Intravascular – those that originate within the cardiovascular system 
Extravascular – those that result from bacteria entering the blood 
circulation through the lymphatic system from another site of infection 
Catheter Related Blood Stream Infection (CRBSI)[13]– 
Catheterrelated infections are an intravascular form of Blood stream 
infections. CRBSIs contribute about 64% of nosocomial BSIs according to 
CDC’s NNIS system (National Nosocomial Infection Surveillance System) 
and is attributed mainly to intravascular catheters particularly Central Venous 
Catheters for which the infection rate is expressed as  number of CRBSIs per 
1000 catheter days. 
 7    
 
Patients having the following risk factors are more prone for HAI[12] 
1) Age > 70 years 
2) Shock 
3) Major trauma 
4) Acute Renal Failure 
5) Coma 
6) Prior antibiotics 
7) Mechanical ventilation 
8) Immunosuppressive drugs like steroids, chemotherapy. 
9) Indwelling catheters 
10) Prolonged ICU stay (> 3 days) 
Epidemiology 
Health care- associated infections(HAI) are an important cause of 
morbidity and mortality and place a significant burden on the health care 
system of which Central venous catheter related blood stream infections 
(CRBSI) account for 11% with an estimated mortality rate of 12 to 25%[15] and 
increased hospital cost[16]. In the United states,15 million CVC days occur in 
intensive care units each year.[14]Majority of CRBSIs are associated with 
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CVCs and in prospective studies, the relative risk for CRBSI is up to 64 times 
greater with CVCs than with peripheral venous catheters. [16]An estimate of 
30,100 central line associated blood stream infections occur in U.S hospitals 
each year.[4] 
Central Venous Catheterization.[4] 
Central line is an intravascular catheter that terminates at or close to the 
heart or in one of the great vessels like Aorta, pulmonary artery, superior vena 
cava, inferior vena cava, Brachiocephalic veins, Internal jugular veins, 
Subclavian veins, External iliac veins, Common iliac veins, Femoral veins and 
umbilical artery / vein in case of neonates. 
Types of Central line[2,4] 
Temporary line – non tunnelled, non implanted catheter. 
Permanent line – tunnelled catheters including dialysis catheters, 
Implanted catheters including ports. 
Central venous catheters are now widely used in intensive care units. 
Like any medical procedure, CVC has specific indications and should be 
reserved for patients who potentially benefit from it.  
  
 9    
 
Indications for Central Venous Catheterization[2] 
1) Pulmonary artery catheterization 
2) Total parenteral nutrition 
3) Acute hemodialysis , plasmapheresis 
4) Cardiopulmonary arrest 
5) Emergency transvenous pacemaker 
6) Hypovolemia, inability to perform peripheral iv 
7) Preoperative preparation 
8) General purpose venous access, vasoactive agents, caustic medications, 
radiologic procedures 
9) Central venous oxygen saturation monitoring 
10) Fluid management of ARDS ( CVP monitoring ).  
Such central venous catheterization can be met with complications such as 
infection, pneumothorax, hemothorax, hematoma, thrombosis, arrhythmia and 
arterial puncture.[17]Of all the complications, Central venous catheter related 
blood stream infection(CRBSI) stands out to be the dreaded Healthcare-
Associated Infection(HAI) for a patient admitted in an Intensive care unit with 
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high morbidity and mortality. Almost 80-90% of Blood stream infections(BSI) 
arising from vascular access are caused by CVCs.[3] 
Factors influencing the risk of acquiring CRBSI[6,16,18] 
1) Catheter characteristics- material, number of lumens, size, coating/ 
impregnation, frequency of catheter manipulations. 
2) Reason for catheterization. 
3) Catheters inserted in emergency situations. 
4) Inexperienced person inserting the line, Improper site preparation, 
anatomical insertion site ,method of catheter insertion, purpose of 
insertion and duration of insertion 
5) Standard of daily line care. 
The administration of parenteral nutrition through intravascular 
catheters , poor personal hygiene, occlusive transparent dressing, 
moisture around the exit site, Staphylococcus nasal colonization and 
contiguous infections support the role of bacterial colonization in the 
pathogenesis of CRBSI. 
6) Patients admitted to intensive care unit are at higher risk than patients 
admitted in other wards and outpatients. 
7) Colonization of patients with hospital acquired organisms. 
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Source of infection for CRBSI[10] 
       Microorganisms may originate from the skin of patients or health care 
workers ,tap water to which entry ports are exposed or other sources in the 
environment. The density of skin flora at the catheter insertion site is a 
major risk factor for CRBSI. Normally counts of 1000-10,000 cfu/cm2 is 
present in jugular and subclavian catheter sites whereas 10 cfu/cm2 at 
antecubital space. 80% of resident microorganisms inhabit the upper 5 
layers of stratum corneum and 20% survive in biofilms within the 
epidermis, sebaceous glands and hair follicles. 
Microbiology 
             Inthe past 2 decades, the antimicrobial resistant organisms such as 
methicillin resistant Staphylococcus aureus, multidrug resistant gram negative 
bacilli and fluconazole resistant Candida species is on the rise. [15] 
The most common aetiological organisms for nosocomial CRBSI[9]are 
Bacteria- Staphylococcus aureus, Coagulase negative 
Staphylococcus,Pseudomonas aeruginosa, Acinetobacterbaumanii, 
Klebsiellapneumoniae ,Citrobacterfreundii, Enterococci and Escherichia coli. 
Fungi- mainly Candida species. 
A prospective study using data from SCOPE(Surveillance and Control of 
Pathogens of Epidemiological importance) which included 24,179 cases of 
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CRBSIs from a 7 year period at 49 hospitals found that the rates of MRSA 
isolates increased from 22% in 1995 to 57% in 2001(p< 0.001) and rates of 
Ceftazidime resistant Pseudomonas aeruginosa isolates increased from 12% in 
1995 to 29% in 2001(p<0.001) and 60% of isolates contained Vancomycin 
resistant Enterococcus faecium. [19] 
Pathophysiology of CRBSI 
            The pathogenesis of CRBSIs can be due to colonisation of catheter( 
from skin flora – extraluminally or from hematogenous seeding - 
intraluminally), due to contamination of the catheter hub or due to infusion of 
the contaminated infusate ( this causes an epidemic which is almost rare ) 
.[15]For short term CVCs(<10 days), the most common mode of colonization is 
along the external surface while for long term CVCs(>10 days), endoluminal 
spread from the hub appears to be the primary mechanism of infection.[16] 
         Direct contact of the microorganism with the catheter surface is required 
for attachment and subsequent colonization which happens by means of 
biofilm formation.[10] When the catheter is introduced into the venous system, 
the circulating plasma proteins collide and bind with the biomaterial which 
further activates the coagulation cascade and complement system attracting 
platelets and polymorphs. All the above process forms a conditioning layer 
that serves as a scaffold for the developing biofilm by providing receptor 
binding sites for newly arrived bacteria.[7] 
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Thus biofilm formation is the pathogenesis behind all device associated 
hospital acquired infections.[21] 
 
About the Biofilm 
Historical perspective 
The first recorded observation concerning biofilm was probably given 
by Henrici in 1933 who observed that water bacteria are not free floating but 
grow upon submerged surfaces.[20] Nearly 40 years ago, Dr.R.J. Gibbons made 
the first report of his observations of polysaccharide glycocalyx formation on 
teeth by Streptococcus mutans.[21] 
Present perspective 
            More recent direct microscopic observations and direct quantitative 
recovery techniques demonstrate that more than 99.9% of bacteria grow as 
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aggregated ‘sessile’ communities attached to surfaces rather than as 
‘planktonic’ or free floating cells in liquid.[10]Biofilms are formed both on 
living tissue as well as nonliving inert material and are responsible for 65% of 
infections treated in the developing world.[9] 
Definition of Biofilm[7] 
           A biofilm is a primitive developmental biological system in which 
spatial organization of the cells within the matrix optimizes the use of 
available nutritional resources. An immobilized enzyme system is formed in 
which the milieu and enzyme activities are constantly changing and evolving 
to an appropriate steady state. This steady state can be radically altered by 
applying physical factors such as high shear force. 
Factors influencing biofilm formation[21] 
The potential causes behind formation of biofilms by bacteria during 
infection are  
1) Protection from harmful conditions in the host(defense) 
2) Sequestration to nutrition rich area(colonization) 
3) Utilization of cooperative benefits(community) 
4) Biofilms normally grow as biofilms and planktonic cultures are an in 
vitro artefact(biofilms as a default mode of growth) .  
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Steps in biofilm formation 
 
 
 
 
 
 
 
 
Steps in biofilm formation[7,8,9,21] 
1) Microbial attachment – microbes get attached to the conditioning layer. 
2) Adhesion and microcolony formation – few minutes after microbial 
attachment, phenotypic changes occur in them and also upregulation of 
genes take place resulting in accumulation of proteins and 
polysaccharides which firmly adhere cells to the substratum. The cells 
continue to divide and the daughter cells thus formed become 
embedded in exopolymer saccharides(EPS) moving in upward and 
outward direction forming microcolonies. Thus the composition of 
microcolonies are 10% to 25% cells and 75% to 90% EPS. 
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3) Dispersion and Dissemination of Biofilm cells – dispersal is 
accompanied by shedding, detachment or shearing but they leave 
behind an adherent layer of cells on the surface to regenerate the 
biofilm. The number of organisms on the catheter tip is related to 
occurrence of bloodstream infection in the patient supporting the 
concept of a critical level of biofilm development above which 
substantial cell detachment and embolism occur. 
Molecular mechanisms behind biofilm formation 
The development and structural integrity of the biofilm depends on 
Quorum sensing(QS). QS is the ability to use extracellular molecules called 
pheromones to allow enhanced communication among bacteria. Pheromones 
are different for gram positive and gram negative bacteria. For gram positive 
organisms, the pheromones are oligopeptides or proteins whereas for gram 
negative bacteria, the pheromones are low molecular weight homoserine 
molecules such as N- acyl homoserine lactone. [7] 
Biofilm recalcitrance to antimicrobials 
The hallmark of biofilm is the innate resistance to antimicrobials and host 
immune responses due to the following factors 
1) Restricted penetration  - The negatively charged EPS restricts the 
positively charged antibiotics into the depths by binding to them and 
also restrict the passage of complement molecules.[10] 
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2) Nutrient limitation – limited nutrients and oxygen in the inners layers 
make the cells metabolically inactive and slow growing when compared 
to the active planktonic cells on the outer layers.[23] 
3) Adaptive responses – due to fluctuations in temperature, pH, osmolarity 
and nutrient availability there occurs genetic alterations with expression 
of multiple stress response genes [21] 
4) Genetic transfer – occurs by means of horizontal exchange of resistant 
plasmids between the biofilm cells[23] 
5) Presence of persister cells -  about 0.1% to 10% of biofilm cells remain 
as persister cells which ensure the survival of biofilm even in the 
escalated concentrations of antimicrobial agents.[10] 
Clinical Presentation 
A patient on CVC who presents with fever or chills, unexplained 
hypotension with no other localising sign is suspected to have CRBSI.[24] Mild 
symptoms are malaise and nausea while severe symptoms are high fever with 
rigors, hypotension, vomiting and changes in mental status.[25] 
        Exit site infection is indicated by the presence of erythema, swelling, 
tenderness and purulent discharge around the catheter exit and the part of the 
tunnel external to the cuff.[16] Severe sepsis and metastatic infectious 
complications such as infective endocarditis, septic arthritis, osteomyelitis, 
spinal epidural ascess and septic emboli can prolong the course of CRBSI.[26] 
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Diagnostic criteria for CRBSI 
CRBSI was defined{ as isolation of the same organism from 
semiquantitative (more than 15 cfu) or quantitative culture (more than 100cfu / 
ml) of a catheter tip and a peripheral blood culture[27] or more than 3-5 fold 
growth in catheter pull through blood when compared to peripheral blood[15] or 
more than 100 cfu/ml growth of catheter pull through quantitative culture [15]} 
with systemic inflammatory response syndrome, after exclusion of other 
infection sources. 
Diagnostic criteria for colonization 
Colonization of the catheter tip was defined{ as the finding of>15 cfu 
of bacteria in semiquantitative culture and>102cfu / ml in quantitative culture 
from the catheter tip in a patient without growth in the peripheral blood culture 
or growth in catheter pull through blood sample with no growth in peripheral 
blood culture or less than 100 cfu/ml growth of catheter pull through sample } 
without clinical symptoms of sepsis.[27] 
Laboratory confirmed Blood stream infection criteria (LCBI).[4] 
LCBI 1 –Patient has a recognized pathogen cultured from one or more blood 
cultures and organism cultured from blood is not related to an infection at 
another site. 
LCBI 2 – Patient has atleast one of the following signs or symptoms : fever ( 
>38°C),chills or hypotension and positive laboratory results are related to an 
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infection at any other site and the same common commensal(i.e. diphtheroids, 
Bacillus sp, Propionibacteriumsp, Coagulase negative Staphylococcus, 
viridans group Streptococci, Aerococcus and Micrococcus) is cultured from 
two or more blood cultures drawn on separate occasions. 
LCBI 3 – Patient <= 1 year of age has atleast one of the following signs or 
symptoms: fever(>38°C), hypothermia (36°C core),apnoea or bradycardia and 
the same common commensal(i.e. diphtheroids, Bacillus sp, 
Propionibacteriumsp, Coagulase negative Staphylococcus, viridans group 
Streptococci, Aerococcus and Micrococcus) is cultured from two or more 
blood cultures drawn on separate occasions. 
Catheter associated blood stream infections(CABSI) –  
A laboratory-confirmed bloodstream infection (LCBI) where central 
line (CL) or umbilical catheter (UC) was in place for >2 calendar days on the 
date of event, with day of device placement being Day 1, and a CL or UC was 
in place on the date of event or the day before. If a CL or UC was in place for 
>2 calendar days and then removed, the LCBI criteria must be fully met on the 
day of discontinuation or the next day.  If the patient is admitted or transferred 
into a facility with a central line in place (e.g., tunnelled or implanted central 
line), and that is the patient’s only central line, day of first access as an 
inpatient is considered Day1.   “Access” is defined as line placement, infusion 
or withdrawal through the line.[4] 
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Methods for diagnosis of CRBSI[15] 
Methods not requiring CVC removal 
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Qualitative 
blood culture 
through device 
One or more blood cultures 
drawn through CVC 
Any growth 87 83 
Quantitative 
blood culture 
through device 
Blood culture drawn through 
CVC, processed by pour 
plates or lysis centrifugation 
>= 100 cfu / ml 77 90 
Paired 
Quantitative 
blood cultures 
Simultaneous cultures drawn 
through CVC and 
percutaneously 
Both cultures 
positive with 
CVC culture 
yielding 5 fold 
higher or more 
than peripherally 
drawn culture 
87 98 
Differential 
time to 
positivity 
Simultaneous blood cultures 
drawn through CVC and 
percutaneously and 
monitored continuously 
Both cultures 
positive with 
CVC positive >= 
2 hours earlier 
than peripherally 
drawn culture 
85 81 
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Methods requiring CVC removal 
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Qualitative 
catheter segment 
culture 
Segment from removed 
CVC is immersed in 
broth media and 
incubated for 24-72 
hours 
Any 
growth 
90 72 
Semiquantitative 
catheter segment 
culture 
A 5 cm segment from 
removed CVC is rolled 
4 times across a blood 
agar plate and incubated 
>= 15 cfu 85 82 
Quantitative 
catheter segment 
culture 
Segment from removed 
CVC is flushed or 
sonicated with broth , 
serially diluted and 
plated on blood agar 
>=1000cfu 83 87 
Microscopy of 
stained CVC: 
Gram stain and 
acridine orange 
staining    
 
Direct visualisation of 
the microorganisms    
 
 84-
100%   
 
97-
100%   
 
 
 Prevention of CRBSI 
The Centre for Disease Control and Prevention(CDC) and Healthcare 
Infection Control Practices Advisory Committee(HICPAC) devised guidelines 
intending to provide Evidence based recommendations for preventing 
CRBSIs. 
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Education, Training and Staffing[28,29] 
1) Educating the healthcare personnel regarding the indications for CVC 
use, proper procedures for insertion and maintenance of CVCs and 
appropriate infection control measures to prevent CRBSIs. 
2) Limiting the staffs in ICUs to decrease CRBSI.  
3) Designate only trained personnel and periodically assess their knowledge. 
Surveillance of Catheter related infection[28] 
1) Inspection and palpation of the catheter sites through intact dressing. 
2) Record the operator, date and time of catheter insertion and removal 
and dressing changes on a standardised form. 
Selection of Catheters and sites[17] 
1) CVCs are recommended only if the benefits outweigh the risks.  
2) Subclavian site is better than jugular or femoral site.  
3) USG guided CVC insertion can be done to reduce the number of 
cannulation.  
4) CVC with minimum number of ports or lumens should be used.  
5) Remove CVC if it is no longer needed. 
6) When aseptic techniques have not been followed in emergent situations, 
replace the CVC within 48 hours. 
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Type of Catheter material [30] 
         Polytetrafluoroethylene (Teflon) or polyurethane catheters have been 
associated with fewer infectious complications than catheters made of 
polyvinyl chloride or polyethylene. 
Hand hygiene and Aseptic technique[14,28,29] 
1) Hand washing with conventional soap or rubbing with Alcohol based 
handrub should be done before and after palpating catheter insertion site, 
before and after inserting , replacing or dressing a CVC. 
2) Aseptic technique for the insertion and care of CVC is a must which 
means wearing sterile gloves. 
Maximal Sterile Barrier Precautions [29] 
A cap, mask, sterile gown, sterile gloves and a sterile full drape for 
insertion of CVC is mandatory. 
Skin Preparation[29,30] 
1) Prepare clean skin with a 0.5% Chlorhexidine preparation with alcohol 
before CVC insertion. If there is a contraindication for chlorhexidine, 
tincture of iodine, an iodophor or 70% alcohol can be used. 
2) Antiseptics should be allowed to dry before insertion of CVC.  
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Catheter Site Dressing Regimens[14] 
1) Use sterile gauze or sterile transparent semipermeable membrane 
dressing to cover the catheter site.  
2) If the site is bleeding or oozing, use gauze dressing until it is resolved. 
3) Replace dressing if it becomes damp, loosened or soiled.  
4) Avoid antibiotic creams as it promotes fungal infection.  
5) Avoid showering over the catheter site.  
6) Replace short term CVC dressings every 2 days for gauze dressings and 
every 7 days for transparent dressings.  
7) Encourage patients to report any changes in the catheter site or any 
discomfort to the healthcare provider. 
Patient cleansing[14] 
            Use a 2% chlorhexidine wash for daily skin cleansing.  
Catheter Securement Devices[14,28] 
Using sutureless securement device avoiding disruption around catheter 
entry site decreases infection.  
Antimicrobial / Antiseptic impregnated Catheters and Cuffs[14,28,30] 
            Even after successful implementation of Comprehensive strategy 
which includes educating staffs, following maximal sterile barrier precautions 
and >0.5% chlorhexidine preparation with alcohol for skin antisepsis, the 
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CRBSI rate is not decreasing then use chlorhexidine / silver sulphadiazine or 
minocycline / rifampin or platinum / silver impregnated CVCs. 
Systemic Antibiotic Prophylaxis[28] 
Do not administer systemic antimicrobial prophylaxis before insertion 
or during use of CVC to prevent colonization or CRBSI. 
Anticoagulants[14] 
Do not routinely use anticoagulant therapy to reduce the risk of catheter 
related infection. 
Replacement of CVCs[14,28] 
1) Select the catheter, insertion technique and insertion site with the lowset 
risk of complications(infectious and non-infectious) for the anticipated 
type and duration of intravenous therapy. 
2) Do not routinely replace the catheters for the purpose of reducing 
infection. 
3) Clinically a patient should be judged for infection elsewhere or for a non-
infectious cause of fever before catheter removal is done. 
4) Use a guidewire exchange to replace malfunctioning non tunnelled 
catheter only if there is no evidence of infection . 
5) Replace any short term CVC if purulence is observed at the insertion site 
which indicates infection. 
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6) Replace all CVCs if the patient is haemodynamically unstable and CRBSI 
is suspected. 
Replacement of Administration sets[14] 
1) In patients receiving blood, blood products or fat emulsions ,tubings 
should be replaced within 24 hours. Otherwise 96 hour interval can be 
given before replacement. 
2) Replace tubing used to administer propofol solutions every 6 or 12 hours. 
Hangtime for parenteral fluids[28] 
1) Complete infusions of lipid containing fluids within 24 hours of hanging 
the fluid. 
2) Complete infusions of blood or other blood products within 4 hours of 
hanging the blood. 
Preparation and Quality control of intravenous admixtures[14,17,28] 
1) Admix all routine parenteral fluids in a laminar flow hood using aseptic 
techniques. 
2) Do not use infusate if the container has leaks, cracks, turbidity, 
particulate matter or if the expiry date has passed. 
3) Use single dose vials for parenteral additives or medications. 
4) If multidose vials are used, refrigerate them and clean the access 
diaphragm with 70% alcohol 
5) Do not use inline filters routinely for infection control purposes. 
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Surveillance[14] 
1) Conduct surveillance in ICUs and other patient populations to 
determine CRBSI rates, monitor trends in those rates and assist in 
identifying lapses in infection control practices. 
2) Express ICU data as the number of catheter associated blood stream 
infections per 1000 catheter days for both adults and children. 
Peter Pronovost et al conducted an intervention study recommending 
procedures such as handwashing, full barrier precautions during the insertion 
of catheter , cleaning the skin with chlorhexidine , avoiding the femoral site if 
possible and removing unnecessary catheters. The median CRBSI rate 
decreased from 2.7 per 1000 catheter days to 0 and the mean rate decreased 
from 7.7 to 1.4 per 1000 catheter days. The incidence rate decreased from 0.62 
to 0.34. [13] 
Considering environmental factors[29] 
1) High quality cleaning and disinfection of all patient care areas is very 
important 
2) The ICU unit should be situated close to the operation theatre and 
emergency department and away from wards 
3) Suitable and safe air quality should be maintained 
4) There should be separate areas for clean storage and waste disposal 
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Performance indicators for prevention of Catheter Associated Blood 
Stream Infection. [28] 
1) Implementation of educational programmes that include didactic and 
interactive components for those who insert and maintain catheters. 
2) Use of maximum sterile barrier precautions during catheter placement. 
3) Use of chlorhexidine for skin antisepsis. 
4) Rates of catheter discontinuation when the catheter is no longer 
essential for medical management. 
Management of CRBSI 
Depends mainly on two strategies 
1) Appropriate and timely administration of systemic antimicrobial 
treatment. [15] 
2) Treatment of the catheter associated biofilm as the source of infection 
either by catheter removal or catheter salvage.[10] 
Empirical broad spectrum antimicrobial therapy is initiated after the 
collection of appropriate samples, depending on the pathogen profile present 
in a given institution and the severity of the patients illness. [10] 
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Antibiotic lock therapy 
 ALT involves installing a higher oncentration of an antibiotic to which 
the causative microbe is susceptible in the catheter lumen.[27] 
Vancomycin at 5 mg/ml is more efficacious in eradicating 
Staphylococci embedded within biofilm.[31] and also for ampicillin resistant 
Enterococci other than Vancomycin resistant Enterococci. 
Ceftazidime, gentamicin or ciprofloxacin can be used for the treatment 
of Gram negative organisms. 
Berrington and Gould studied that bacteriostatic agents be used better 
for ALT.[32] 
Atleast 1-5 ml of the ALT solution should be used to fill catheter 
lumen. [33] 
It is suggested that the dwell time for Alt be better ≥12 hours for about 
14 days. [22] 
Ethanol Lock Therapy (ELT) [22] 
Ethanol is an antiseptic agent which exhibits bactericidal and fungicidal 
activity against a wide range of organisms including Gram-negative and 
Gram-positive bacteria. It is readily available, inexpensive, and currently no 
resistance to microorganisms has been discovered. In contrast to antibiotic 
lock therapy, ethanol works by denaturisation therefore the effect does not 
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depend on microorganism resistance or sensitivity. For these reasons this 
therapy has sparked interest within the medical field to safely develop a 
standard process for its use in the prevention and treatment of CRBSI. 
Eliminating Biofilms on medical devices [22] 
The invitro testing models use a variety of antimicrobials and other 
chemical substances for testing. 
Antimicrobials 
Antimicrobials such as Rifampin, alone and along with glcopeptides, 
fluoroquinolones and macrolides have shown effect in reducing the EPS of 
biofilm biomass. Gentamicin has shown to reduce the Mininmum biofilm 
inhibitory concentration of ampicillin, Vancomycin and linezolid for 
Enterococcus. [34] 
Chelating agents 
Chelating agents for calcium , magnesium and iron such as EDTA( 
Ethylene Diamine Tetra Acetic acid) is found to have antimicrobial activities 
against a spectrum of organisms. EDTA in combination with antibiotics like 
minocycline, tigecycline and gentamicin can also be used.[35,36,37] 
       Sodium citrate has also shown effect against biofilm of most Gram 
positive organisms. A combination of 7% trisodium citrate, 0.05% methylene 
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blue,0.15% methyl paraben and 0.015% propyl paraben exhibit antibiofilm 
activity of Staphylococcus aureus.[38] 
         A combination of 4% trisodium citrate and 30% ethanol can also be used 
against biofilm of S.aureus, S.epidermidis, P.aeruginosa and E.coli for 72 
hours in vitro. [39] 
Ethanol 
20% ethanol for 24 hours , 40% for 1hour, 60%- 80% for 1 min has 
shown a promising invitro activity against 24 hour biofilms of S.epidermidis, 
S.hominis and S.capitis. 25% ethanol along with minocycline(3mg/ml) and 
EDTA(30 mg/ml) resulted in complete eradication of S.aureus biofilms.[22] 
Biofilm dispersant 
Dispersants such as oxidizing biocides like chlorine, surfactants and 
enzymes such as cis 2- decanoic acid (an unsaturated fatty acid produced by 
P.aeruginosa) can induce dispersion of biofilm cells which along with 
bactericidal agents can prevent reattachment. [22] 
Bacteriophage 
Polysaccharide depolymerases produced by some phage strains can 
degade the biofilm EPS.[22] 
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N-acetylcysteine 
A mucolytic which interferes with the exopolysaccharide formation in 
biofilms.[40] 
GlmU enzyme inhibitor 
N-ethyl maleimide and Protamine sulphate are the inhibitors against 
GlmUenzyme(N acetylglucosamine-1-phosphate uridyltransferase) , an 
enzyme required for peptidoglycan synthesis and lipopolysaccharide synthesis 
in Gram positive and Gram negative bacteria respectively.[40] 
Silver nanoparticles[20] 
Nanotechnology is useful for biofilm penetration and reducing biofilm 
formation. AgNPs hydrogel hybrid with different sizes of AgNPs can be 
effectively employed as antibacterial agents. 
  
MATERIALS AND 
METHODS 
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MATERIALS & METHODS 
Ethics consideration  
Ethics committee clearance [EC RegNo.ECR/270/Inst./TN/2013] was 
obtained from the Institutional Ethics Committee, Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai-3. 
Study design   : Cross sectional study 
Study period   : October 2014 to August 2015 
Study setting: 
 The study was conducted in the Institute of Microbiology in association 
with the Intensive Medical, Surgical and Trauma care units, Madras Medical 
College &RGGGH . All patients satisfying the following inclusion criteria 
were recruited. Patients’ clinical history was collected by a standard proforma.           
Sample Size  : 105 
Inclusion criteria: 
• ICU patients >18ys of age with indwelling central venous catheter who 
developed symptoms of blood stream infections after 48hrs of 
catheterization were included in the study. 
• fever (temp ≥ 38°C) without any other known cause in patients with 
indwelling central venous catheters. 
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• Overt catheter site infection, i.e. any 2 of the following- erythema, 
tenderness and purulent exudate. 
Exclusion criteria: 
• Patients diagnosed with clinical syndromes such as pneumonia, urinary 
tract infection, cellulitis, septicaemia and infective endocarditis were 
excluded . 
•  Patients with Retroviral disease. 
• Patients on immunosuppressive drugs. 
• Patients in whom central venous catheterization was done elsewhere.                    
Samples were collected as per the following categories of patients based on 
the clinical status and indication. 
Category[1]- Patients with suspected CRBSI with maintenance Central 
venous catheterization 
      1)Catheter blood sample 
      2)Peripheral blood sample 
Peripheral blood samples were collected within 15 minutes of 
collection of central venous blood. 
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Category[2]-Patients with suspected CRBSI in whom maintenance 
catheterization is not indicated and central venous catheter can be 
removed 
1) Catheter tip sample 
       2) Peripheral blood sample 
Peripheral Blood sample should be collected within 15 minutes of 
catheter removal 
Category[3]- For patients with difficult peripheral vein access  
1) Catheter blood sample (For Quantitative culture through device) 
SAMPLE COLLECTION: 
Under strict aseptic precautions samples were collected from the 
patients and transported immediately to the laboratory appropriately for further 
process. 
Method for Catheter tip collection 
              The skin was disinfected with 70% alcohol[42]or 2%chlorhexidine[43] 
before catheter removal. The catheter was held with the proximal end, 
removed aseptically without touching the skin and the distal 5 to 6 cm cut off 
with sterile scissors into a sterile tube which was sent to the laboratory within 
30 minutes to avoid drying.[42] 
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Method for Catheter blood collection 
· For Qualitative culture 
The catheter hub was cleaned with 70% alcohol and allowed to 
evaporate after which 10 ml of blood was collected and added to Tryptic soy 
broth . 
· For Quantitative culture 
          The catheter hub was cleaned with 70% alcohol and allowed to 
evaporate after which 1ml of blood was collected and heparinised(0.1ml of 
50,000IU heparin).[44] 
Method of Peripheral blood Collection 
The venepuncture site was first cleaned with povidone iodine and then 
with 70% alcohol. A tourniquet was applied above the venepuncture site. With 
sterile aseptic precautions, about 10ml of blood was obtained and inoculated 
into a blood culture bottle containing 50 mlTryptic soy broth.[45] 
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SAMPLE PROCESSING: 
1. Catheter tip: 
Semiquantitative Maki’s Roll plate method (Exoluminal method) 
Using sterile forceps, the catheter tip was taken from the sterile tube 
and placed on the blood agar . The tip was then rolled back and forth about 
four times over the entire surface of agar.[42] 
Quantitative Brun Buisson’s tip flush method ( Endoluminal method) 
Sterile normal saline 1ml was dripped into the lumen of the tube inside 
a sterile tube and 0.1ml of the flushed material was evenly spread onto the 
blood agar plate.[47] 
2. Catheter blood: 
Qualitative culture 
10 ml of blood which was collected and added to Tryptic soy broth was 
incubated at37°C . Subcultures onto Mac conkey agar and sheep Blood agar 
plates were done once on the first day and twice within 3 days. The broth was 
incubated and inspected for upto 5-7 days with a final subculture. [46] 
Quantitative culture 
1ml of blood which was collected and heparinised(0.1ml of 50,000IU 
heparin) was added to  20 ml of melted Tryptic soy agar after cooling it to 45-
50°C, poured into sterile petri dishes, incubated at37°C overnight and colonies 
counted.[43] 
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3. Peripheral blood 
10 ml of blood which was collected in 50 ml of Tryptic soy broth was 
incubated at37°C for 48 hours and subcultured onto Mac conkey Agar and 
Blood Agar plates, incubated at37°C . Subcultures onto Mac conkey agar and 
sheep Blood agar plates were done once on the first day and twice within 3 
days. The broth was incubated and inspected for up to 5-7 days with a final 
subculture. [46] 
IDENTIFICATION OF MICROORGANISMS: 
The colonies grown were further identified using Gram’s staining and 
Biochemical reactions.[48] 
Gram staining:-  
Smears were prepared from the growth, followed by gram staining. The 
control strains used were S. aureus (ATCC 25923) and E.coli (ATCC 25922). 
           According to Gram reaction, the organisms were subjected to 
biochemical reactions using appropriate quality controls. [48] 
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Biochemical reactions : 
For identification of Gram positive cocci  
1)  Catalase test  
2) Modified Oxidase test  
3)  Coagulase test  
4)  Urease test  
5) Aminoacid decarboxylation test(Lysine and Ornithine)  
6)  Arginine dihydrolation test 
6)  Sugar fermentation test with glucose, lactose, sucrose, maltose, 
mannose, mannitol,  xylose. 
7)  Bile esculin test  
8)  Differential discs-Novobiocin[5µg,furazolidone[100µg] ,Bacitracin 
[0.04 units/disk] 
For identification of Gram negative bacilli  
1)   Hanging drop – to check for motility  
2)  Catalase test  
3)  Oxidase test  
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4)  Nitrate reduction test   
5)  Indole production test 
6)  Methyl red test  
7) VogesProskauer test  
8)  Citrate utilization test  
9)  Urease test  
10)  Triple sugar iron agar test  
11)  Sugar fermentation test Glucose, Lactose, Sucrose ,maltose and 
mannitol. 
12)  Amino acid decarboxylation tests  
13)  Hugh-Leifson’s Oxidation Fermentation test  
For identification of Candida species:[52] 
1) Germtube test 
2) Fermentation of 2% sugars 
3) Chrome Agar  
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ANTIMICROBIAL SUSCEPTIBILITY TESTING 
The antimicrobial sensitivity of aerobic bacterial isolates was 
performed on Mueller Hinton agar (MHA) plates by standardized Kirby Bauer 
disc diffusion technique as per the CLSI (Clinical Laboratory Standards 
Institute) guidelines M100-S24 [January 2014][50]. Antifungal susceptibility 
testing according to CLSI guidelines M44-A[2004]. [51] 
ANTIBACTERIAL SUSCEPTIBILITY TESTING[49] 
Three to five identical colonies were picked from an overnight grown 
primary agar plate with a sterile loop and were suspended in 0.5ml of sterile 
saline. The turbidity was matched with 0.5 McFarland turbidity standards. A 
fresh, sterile cotton tipped swab was dipped into this suspension and the 
excess of inoculum was removed by pressing it against the sides of the tube. 
The surface of Mueller Hinton agar plate was inoculated, by starting at the top 
and streaking back and forth from edge to edge. The plate was rotated 
approximately at 60° and swabbing repeated for three times. The antibiotic 
discs were placed on the plate, so that even contact was ensured using sterile 
forceps after 15 minutes of inoculation and incubated aerobically at 37°C . 
After 18-24 hours of incubation, the diameter of the clear zone around the disk 
was measured under transmitted light with measuring scale and results were 
interpreted as susceptible, intermediate or resistant as per the CLSI criteria. 
The quality control for antimicrobial susceptibility testing was done with 
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standard strains of E.coli (ATCC 25922), S. aureus (ATCC 25923) and P. 
aeruginosa (ATCC 27853). 
The drugs(Himedia) used for Gram positive organisms were:- [50] 
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Penicillin 10 units Staphylococcus 
species 
≥ 29 - ≤ 28 
Cefoxitin 30 µg Staphylococcus 
aureus 
≥ 22 - ≤ 21 
CoNS ≥ 25 - ≤ 24 
Amikacin 30 µg Staphylococcus 
species 
≥ 17 15-16 ≤ 14 
Erythromycin 15 µg Staphylococcus 
species& 
Enterococcus 
species 
≥ 23 14-22 ≤13 
S.pneumoniae ≥ 21 16-20 ≤15 
Ciprofloxacin  5 µg Staphylococcus 
species& 
Enterococcus 
species 
≥ 21 16-20 ≤15 
Trimethoprim- 
Sulfamethoxazol
e 
1.25/ 
23.75µg 
S.pneumoniae ≥ 19 16-18 ≤15 
Tetracycline 30 µg Enterococcus 
species& 
Staphylococcus 
species 
≥ 19 15-18 ≤14 
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The drugs (Himedia)used for Gram negative organisms were:- [50] 
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Amikacin 30 µg Enterobacteriaceae 
&Pseudomonas 
aeruginosa 
≥ 17    15-16 ≤ 14 
Gentamicin 10 µg Enterobacteriaceae 
&Pseudomonas 
aeruginosa 
≥15    13-14 ≤12 
Cefotaxime 30µg Enterobacteriaceae 
 
≥26 23-25 ≤22 
Ceftazidime 30µg Pseudomonas 
aeruginosa 
≥18  15-17 ≤14 
Ciprofloxacin  5 µg Enterobacteriaceae 
&Pseudomonas 
aeruginosa  
≥ 21   16-20 ≤15 
 
 
Cotrimoxazole 
 
1.25/  
23.75μg  
 
 ≥16 11-15 ≤10 
Piperacillin-
tazobactam 
100µg/10 
µg 
Pseudomonas 
aeruginosa 
≥21    15-20 ≤14 
Tetracycline 30 µg Enterobacteriaceae 
 
≥15 12-14 ≤11 
Imipenem 10μg  
 
Enterobacteriaceae 
P.aeruginosa 
Acinetobacter sp. 
≥23 
≥19 
≥16 
20-22 
16-18 
14-15 
≤19 
≤15  
≤13 
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ANTIFUNGAL SUSCEPTIBILITY TESTING[51] 
         This method was carried out following the M 44-A CLSI guidelines 
using fluconazole and voriconazole discs (Himedia). 
Antifungal 
disc 
Disc content 
Diameter of zone of inhibition in mm 
 
Sensitive 
 
Susceptible 
Dose 
Dependent 
Resistant 
Fluconazole 
 
25 µg ≥17 14-16 ≤13 
Voriconazole 
 
1 µg ≥17 14-16 ≤13 
 
Inoculum preparation and application of discs:[52] 
· With a sterile bacteriological loop, 3- 5 yeast colonies were taken from 
the culture grown on SDA and emulsified in 5ml of sterile saline.  
· The yeast suspension was matched to a 0.5 McFarland standards.  
· By using a sterile cotton swab, the suspension was streaked in three 
directions on to the surface of a Mueller Hinton Agar plate 
supplemented with 2% glucose and 0.5µg/ml methylene blue. 
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· By using sterile forceps,fluconazole and voriconazole discs were placed 
on the surface of the agar.  
 The plates were incubated at 37oC. After 24 hours of incubation, the diameter 
of zone of inhibition was measured and interpreted as sensitive or resistant 
according to the CLSI guidelines. Quality control strain used-ATCC Candida 
albicans 90028. 
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Detection of methicillin resistance in Staphylococcus aureus and Coagulase 
negative Staphylococci(CoNS) isolates by cefoxitin disc diffusion test [50]: 
All Staphylococcus aureus and Coagulase negative 
Staphylococci(CoNS) isolates were subjected to cefoxitin disc diffusion test. 
Cefoxitin is used as a surrogate for mecA-mediated oxacillin resistance. The 
bacterial suspension of test isolateswere matched to a 0.5 McFarland standards 
and lawn cultured on Mueller Hinton Agar plates separately.Cefoxitin(30µg) 
disc were placed on the surface of lawn culture of the isolates. The plates were 
incubated in ambient air at 35°Cfor 24 hours.Quality control strain used - 
Staphylococcus aureus ATCC 25923. 
Interpretation as per CLSI guidelines:  
Isolate Sensitive 
Zone of inhibition 
(mm) 
Resistant 
Zone of inhibition 
(mm) 
Staphylococcus aureus and 
Staphylococcus lugdunensis 
≥22mm ≤21mm 
Coagulase negative 
Staphylococci except 
Staphylococcus lugdunensis 
≥25mm ≤24mm 
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Screening Test for Extended -Spectrum β-Lactamases (ESBLs) in 
Enterobacteriaceae isolates [50] 
 All the Enterobacteriaceae isolates were subjected to initial screening 
test for Extended -Spectrum β-Lactamases by using Cefotaxime and 
Ceftazidime discs by disc diffusion as per CLSI guidelines. The use of more 
than one antimicrobial agent for screening improves the sensitivity of ESBL 
detection. 
Procedure: 
The bacterial suspension of test isolates were matched to a 0.5 McFarland 
standards and lawn cultured on Mueller Hinton Agar plates separately. 
Ceftazidime (30 µg) and Cefotaxime(30 µg) discs were placed on the surface 
of lawn culture of the isolates. The plates were incubated in ambient air at 
37°Cfor 16-18 hours. 
Interpretation: 
Ceftazidime zone ≤22 mm ,Cefotaxime zone ≤27 mm may indicate ESBL 
production.  
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MINIMUM INHIBITORY CONCENTRATION BY EPSILOMETER 
TEST  (E-TEST)[53] 
All MRSA isolates were subjected to MIC estimation against  
Vancomycin by using E-test method (HI-MEDIA).  
The E-test strips contains antimicrobial agent with a continuous 
exponential gradient of antibiotics from 0.016µg to 256 µg immobilized on 
porous paper material  and MIC values printed on both sides identically .  
Procedure:  
The strains were inoculated into tubes containing 2ml of peptone water. 
The suspension was sreaked onto the Mueller Hinton Agar  with2% Nacl   to 
give a lawn culture. E-test strips were placed on the inoculated plates. The 
plates were incubated at 37°C for 24 hours  and reading was taken the next 
day. MIC of the drug was taken at the point where the ellipse intersects the 
MIC scale on  the strip. Control strain ATCC Staphylococcus aureus 25923 
were tested in parallel.  
Interpretation: As per CLSI guidelines  
MIC value Interpretation 
≤2 µg/ml sensitive 
4-8 µg/ml intermediate 
≥16 µg/ml resistant 
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BIOFILM DETECTION METHODS 
Tube method[54] 
10 ml of Tryptic soy broth with 1% glucose was inoculated with loopful 
of microorganisms from overnight culture plates, then incubated for 24 hours 
at 37°C. The tubes were then decanted and washed with Phosphate buffer 
Saline (pH- 7.3). The dried tubes were stained with 0.1% crystal violet.Excess 
stain was removed with deionized water and dried in inverted position. 
Positive control- Pseudomonas aeruginosa ATCC 27853 
Negative control- Escherichia coli ATCC 25922 
Interpretation: 
Positive – Visible film lining the walls and bottom of the tube 
Scoring: 0- absent, 1-weak, 2- moderate, 3- strong 
Ring formation at the liquid interface is considered negative. 
Congo red agar method[54] 
The Congo red agar medium consists of Brain heart Infusion broth( 37 
g/ L ), sucrose(50 g/L), agar no.1(10g/L) and Congo red stain(0.8 g/L). Congo 
red was prepared as concentrated aqueous solution and autoclaved at121°C for 
15 mins separately and then added to the agar cooled to 55°C. Plates were 
inoculated and incubated aerobically for 24 to 48 hours at 37°C. 
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Positive control- Pseudomonas aeruginosa ATCC 27853 
Negative control- Escherichia coli ATCC 25922 
Interpretation: 
Strong positive – black colonies with dry crystalline consistency 
Intermediate – black colonies with no crystalline consistency 
Weak – Pink colonies with occasional darkening at centres. 
Microtitre plate method[55] 
Isolates from fresh agar plates were inoculated in TSB with 1% glucose 
and incubated for 24 hours at 37°C and then diluted (1 in 100 ) with fresh 
medium. 200µl of the diluted cultures was inoculated into individual wells of 
sterile polystyrene flat bottom tissue culture platesand controls were 
used(blank well, broth control, dye control and fixative control). The tissue 
culture plate was incubated for 48 hours at 37°C. after incubation , the 
contents of each well was gently removed by tapping the plates. The wells 
were washed with 200µl of PBS(pH- 7.2) to remove free floating planktonic 
bacteria. Biofilms formed by adherent bacteria were fixed with 2% sodium 
acetate and stained with 250µl of 1% crystal violet solution . The plates then 
incubated at room temperature for 20 minutes. Excess stain was rinsed off by 
thorough washing with 250µl of deionised water for 4 times. Adherent cells 
which usually formed biofilm on side walls was uniformly stained with crystal 
violet. Crystal violet stained biofilm was solubilised in 200µl of 95% ethanol 
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to extract the violet colour to quantify it. Optical densities of stained adherent 
bacteria was determined at the wavelength of 570nm using Spectrophotometer. 
These OD values were considered as the index of bacteria adhering to surface 
and forming biofilms. 
Positive control- Pseudomonas aeruginosa ATCC 27853 
Negative control- Escherichia coli ATCC 25922 
Interpretation: 
ODc(optical densitycut off value)= average OD of negative control +                                       
3×SD(standard deviation) of negative control 
Average OD value Biofilm production 
>4× ODc Strong 
<2× ODc - ≤4× ODc Moderate 
≤ 2× ODc Weak / Negative 
 
  
 RESULTS 
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RESULTS 
The study group included 105 patients admitted in Medical, Surgical 
and Trauma Intensive Care Units with indwelling Central Venous Catheter. 
Among the study group,69(66%)were male patients and 36(34%)were female 
patients.  
            The patients comprising the study group were from 3 intensive care 
units in the distribution of  
Medical Intensive Care Unit-34 patients (32%) 
Surgical Intensive Care Unit -46 patients(44%)  
Trauma Intensive Care Unit -25 patients(24%) 
            Among the 105 patients who were clinically suspected to have CRBSI, 
16 patients had Laboratory Confirmed CRBSI . So the infection rate was 
15.23%. The patients had CVC insertion either on an emergency indication 
(67 patients ) or on an elective indication (38 patients). The commonest 
specific indication for catheterization was Lack of peripheral venous access 
among patients followed by Total parenteral nutrition along with blood 
transfusion, fluid replacement during surgery, to resuscitate the patient from 
shock, Central venous pressure monitoring and Dialysis. 
              The results obtained from each and every patient were consolidated 
and depicted in tables and charts as follows where  
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No. of patients (n) stand for the total number of patients with clinically 
suspected CRBSI [n=105] and No. of CRBSI stands for the number of 
patients with laboratory confirmed CRBSI [n=16] 
Table 1 : Age and Gender wise distribution of study recruits with clinical 
suspicion of CRBSI (n=105) 
Age group Males(n=69) Females(n=36) Total(%) 
18-29 years 9 9 18 (17) 
30-39 years 15 9 24(23) 
40-49 years 20 7 27(26) 
50-59 years 12 5 17(16) 
60-69 years 8 4 12(11) 
70-80 years 5 2 7(7) 
Total 69 36 105 
 
26% of the study recruits belong to the age group of 40-49 years and 
most of them are male patients. 
Chart1: Age and Gender wise distribution of study recruits with clinical 
suspicion of CRBSI(n=105) 
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Table2 : Age wise distribution of study recruits(n=105)having Laboratory 
Confirmed CRBSI(N=16) 
Age group No. of 
patients(n=105) 
No. of  
CRBSI(N=16) (%) 
18-29 years 18 3(19) 
30-39 years 24 2(12) 
40-49 years 27 3(19) 
50-59 years 17 5(32) 
60-69 years 12 1(6) 
70-80 years 7 2(12) 
Total 105 16 
 
32% of patients had laboratory confirmed CRBSI in the age group of 
50-59 years when compared to other age groups. 
Chart2 :Age wise distribution of study recruits(n=105)having Laboratory 
Confirmed CRBSI(N=16) 
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Table 3 : Distribution of patients having CRBSI in Intensive care units 
(n=105) 
Intensive Care Unit No. of patients(n=105) No. of CRBSI (%) 
Medical 34 6 (17.64) 
Surgical 46 6 (13.04) 
Trauma 25 4 (16) 
Total 105 16 (15.23) 
 
The overall incidence was found to be 15.23% . 
Chart 3 :Distribution of patients having CRBSI in Intensive care units 
(n=105) 
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Table 4 : Correlation of the Emergency/Elective indication for CVC 
insertion with CRBSI(n=105) 
 
Indication of 
CVC insertion 
No.of patients No. of CRBSI(%) 
Emergency 67 13(81.25) 
Elective 38 3(18.75) 
Total 105 16 
 
Emergency indication causes a higher rate of CRBSI (81.25%) and the 
difference is statistically significant ( p = 0.006 ) 
Chart 4 : Correlation of the Emergency/Elective indication for CVC 
insertion with CRBSI(n=105) 
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Table 5 :Distribution of the Specific Indications for CVC insertion with 
CRBSI(n=105) 
Indication for CVC 
insertion 
No.of patients 
(n=105) 
No.ofCRBSI(%) 
Fluid replacement during 
surgery 
20 3(18.75) 
To resuscitate the patient 
from shock 
17 3(18.75) 
Lack of peripheral venous 
access 
27 4(25) 
Blood transfusion and Total 
parenteral nutrition 
23 4(25) 
Central Venous Pressure 
monitoring 
13 2(12.5) 
Dialysis 5 - (0) 
Total 105 16 
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Table 6 : Correlation of the site of CVC insertion with CRBSI(n=105) 
Site of CVC 
insertion 
No.of patients No.ofCRBSI(%) 
Subclavian site 52 7(13.46) 
Jugular site 30 5(16.67) 
Femoral site 23 4(17.39) 
Total 105 16 
 
        The most common site for CVC insertion was Subclavian site whereas 
CRBSI rate was highest with femoral site of insertion(17.39%). 
Chart 5: Correlation of the site of CVC insertion with CRBSI(n=105) 
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Table 7: Correlation of Duration of Catheterization with CRBSI 
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IMCU ≤ 7 days 23 14 79 1 12.65 
>7 days 29 20 319 5 15.67 
ISCU ≤ 7 days 35 27 213 2 9.38 
>7 days 28 19 245 4 16.32 
ITCU ≤ 7 days 16 10 68 1 14.70 
>7 days 26 15 202 3 14.48 
TOTAL  157 105 1126 16 14.20 
 
Incidence of CRBSI in patients with ≤ 7 days of catheterization in all 
three intensive care units was 7.84% 
Incidence of CRBSI in patients with >7 days of catheterization in all 
three intensive care units was 22.22% 
Infection rate per 1000 device days in patients with ≤ 7 days of 
catheterization in all three intensive care units was 11.11 per 1000 device 
days 
Infection rate per 1000 device days in patients with > 7 days of 
catheterization in all three intensive care units was 15.66 per 1000 device 
days 
            There was significant statistical difference between the incidence and 
infection rates in patients with ≤ 7 days of catheterization when compared with 
the incidence and infection rates in patients with > 7 days of catheterization 
(p= 0.004) 
 61   
 
 Table 8 : Distribution of the categories of sample collected (n=105) 
 
Category of 
sample collected 
No.of 
patients 
(%) 
Samples collected 
Catheter 
blood 
Catheter 
tip 
Peripheral 
blood 
Category 1 43(41) 43 ND 43 
Category 2 36(34) ND 36 36 
Category 3 26(25) 26 ND ND 
Total 105 181 samples collected 
ND – Not Done 
Chart 6 :Distribution of categories of samples collected(n=105) 
 
 
NOTE: 
Category[1]-Patients with suspected CRBSI with maintenance Central venous 
catheterization 
Category[2]-Patients with suspected CRBSI in whom maintenance 
catheterization is not indicated and central venous catheter can be removed 
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25%
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Table 9 : Culture positivity of Category 1 samples(n=43) 
 
Culture 
positivity 
Peripheral blood 
culture positive 
Peripheral blood 
culture negative 
Total 
Catheter blood 
culture positive 
7 15 22 
Catheter blood 
culture negative 
- 21 21 
Total 7 36 43 
 
Table 10 : Culture positivity of Category 2 samples(n=36) 
 
Culture 
positivity 
Peripheral blood 
culture positive 
Peripheral blood 
culture negative 
Total 
Catheter tip 
culture positive 
5 19 24 
Catheter tip 
culture negative 
- 12 12 
Total 5 31 36 
 
Table 11: Culture positivity of Category 3 samples(n=26) 
 
Culture positive Culture 
negative ≥100 cfu/ml <100 cfu/ml 
4 7 15 
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Table 12 :Distribution of patients in IMCU(with CRBSI) with respect to 
their clinical diagnosis (n=34) 
Clinical diagnosis No.of 
patients(n=34) 
No.ofCRBSI(%) 
Acute CVA 9 2(33.33) 
COPD with Type 2 
Respiratory failure 
5 1(16.67) 
Post natal PPH with 
Acute renal failure 
3 -(0) 
DCLD with 
Hepatoencephalopathy 
4 1(16.67) 
Poisoning, Snake bite 6 1(16.67) 
Autoimmune disorders 7 1(16.67) 
TOTAL 34 6 
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Table 13 :Distribution of patients in ISCU(with CRBSI) with respect to 
their clinical diagnosis (n=46) 
 
Clinical diagnosis No.of patients 
(n=46) 
Patients with 
CRBSI(%) 
Intestinal 
obstruction 
12 1(16.67) 
Hollow viscus 
perforation 
13 3(50) 
Blunt injury 
abdomen 
5 1(16.67) 
Acute pancreatitis 6 - 
Multinodular goitre 
thyroid 
3 - 
Splenectomy cases 3 - 
Vascular injury 
cases 
4 1(16.67) 
TOTAL 46 6 
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Table 14 :Distribution of patients in ITCU(with CRBSI) with respect to 
their clinical diagnosis (n=25) 
 
Clinical 
diagnosis 
No.of patients Patients with CRBSI(%) 
RTA with 
Polytrauma 
11 1(25) 
RTA with 
head injury 
5 1(25) 
Polytrauma 
with vascular 
injury 
3 1(25) 
Hydrocephalus 
with VP shunt 
4  
Self fall with 
Loss of 
consciousness 
2 1(25) 
TOTAL 25 4 
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Out of 105 patients with Central Venous Catheterization in the study 
group, bacteria were isolated from 15 patients (Laboratory Confirmed CRBSI) 
of which 11 were gram negative organisms(68.75%) and 4 were gram positive 
organisms(25%). Candida albicans was isolated from one patient(6.25%). 
Table 15: Culture profile of microorganisms causing CRBSI(n=16) 
Microorganisms No.of isolates Percentage 
Pseudomonas aeruginosa 4 25 
Klebsiellapneumoniae 3 18.75 
Acinetobacterbaumanii 2 12.5 
Klebsiellaoxytoca 1 6.25 
Proteus vulgaris 1 6.25 
Staphylococcus aureus 3 18.75 
Staphylococcus epidermidis 1 6.25 
Candida albicans 1 6.25 
TOTAL 16 100 
 
Chart 7: Culture profile of microorganisms causing CRBSI 
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Table 16: Percentage of Antimicrobial Susceptibility Pattern in Gram 
negative organisms 
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Pseudomonas 
aeruginosa (n=4) 
75 25 25 NT NT 100 100 25 NT 
Klebsiellapneumon
iae (n=3) 
66 33 33 33 33 100 66 NT 0 
Acinetobacterbaum
anii (n=2) 
50 0 0 100 50 100 100 0 NT 
Klebsiellaoxytoca 
(n=1) 
100 100 0 0 100 100 100 NT 0 
Proteus vulgaris 
(n=1) 
100 0 0 0 100 100 100 NT 0. 
 
NT –   Not Tested 
AK  -  Amikacin  
GEN  - Gentamicin 
CIP  - Ciprofloxacin 
COT - Cotrimozazole 
TET  - Tetracycline 
IMI  - Imipenem 
PT  - Piperacillin Tazobactum 
CZ  - Ceftazidime 
CTX  - Cefotaxime  
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Table 17: Antimicrobial susceptibility pattern of Gram positive organisms 
 
Gram positive organism 
isolated 
PEN ERY COT TET CIP AK GEN 
Methicillin Resistant 
Staphylococcus aureus 
(n=2) 
0 50 50 50 50 100 50 
Methicillin sensitive 
Staphylococcus aureus 
(n=1) 
0 0 100 100 100 100 100 
Methicillin sensitive 
Staphylococcus 
epidermidis (n=1) 
0 0 100 100 100 100 0 
 
PEN - Penicilin  
ERY - Erythromycin  
AK  -  Amikacin  
GEN  - Gentamicin 
CIP  - Ciprofloxacin 
COT - Cotrimozazole 
TET  - Tetracycline 
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Table 18: ESBL producers among Enterobacteriaceae(n=5) 
 
Organism No. of ESBL 
producers 
Percentage 
Klebsiellapneumoniae 
(n=3) 
3 100% 
Klebsiellaoxytoca 
(n=1) 
1 100% 
Proteus vulgaris 
(n=1) 
1 100% 
 
Table 19 : Sensitivity of MRSA isolates to Vancomycin by MIC 
 
No.ofMRSA isolates Sensitive MIC < 2µg/ml Resistant MIC> 2µg/ml 
2 2  - 
 
Table 20: Antifungal susceptibility pattern of Candida albicans by disc 
diffusion 
 
Fungus isolated Fluconazole Voriconazole 
Candida albicans (n=1) 100% 100% 
 
Biofilm formation of the isolates were tested by three methods namely 
tube method, Microtitre plate method and Congo red agar method with the 
results depicted in tables and charts below 
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Table 21:Biofilm formation of different organisms by tube method 
Organisms tested for 
biofilm 
Strong 
biofilm 
formation(%) 
Moderate 
biofilm 
formation(%) 
Weak biofilm 
formation(%) 
Pseudomonas 
aeruginosa (n=4) 
25 - 75 
Klebsiellapneumoniae 
(n=3) 
33 33 34 
Acinetobacterbaumanii 
(n=2) 
- 100 - 
Klebsiellaoxytoca (n=1) - 100 - 
Proteus vulgaris (n=1) - - 100 
Methicillin Resistant 
Staphylococcus aureus 
(n=2) 
50 50 - 
Methicillin sensitive 
Staphylococcus aureus 
(n=1) 
- - 100 
Methicillin sensitive 
Staphylococcus 
epidermidis (n=1) 
- - 100 
Candida albicans (n=1) - - 100 
 
Chart 8 : Biofilm formation by Tube method 
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Table 22:Biofilm formation of different organisms by microtitre plate 
method 
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Pseudomonas aeruginosa (n=4) 25 25 50 
Klebsiellapneumoniae (n=3) 67 33 - 
Acinetobacterbaumanii (n=2) 100 - - 
Klebsiellaoxytoca (n=1) 100 - - 
Proteus vulgaris (n=1) - - 100 
Methicillin Resistant Staphylococcus 
aureus (n=2) 
100 - - 
Methicillin sensitive Staphylococcus 
aureus (n=1) 
- - 100 
Methicillin sensitive Staphylococcus 
epidermidis (n=1) 
- - 100 
Candida albicans(n=1) - - 100 
 
Chart 9 : Biofilm formation by microtitre plate method 
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Table 23:Biofilm formation of different organisms by Congo red agar 
method 
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Pseudomonas aeruginosa (n=4) 25 50 25 
Klebsiellapneumoniae (n=3) 67 33 - 
Acinetobacterbaumanii (n=2) 100 - - 
Klebsiellaoxytoca (n=1) 100 - - 
Proteus vulgaris (n=1) - - 100 
Methicillin Resistant Staphylococcus 
aureus (n=2) 
100 - - 
Methicillin sensitive Staphylococcus 
aureus (n=1) 
- - 100 
Methicillin sensitive Staphylococcus 
epidermidis (n=1) 
- - 100 
Candida albicans(n=1) - - 100 
 
Chart 10 : Biofilm formation by Congo red agar method 
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Table 24: Comparison of biofilm formation of different organisms by all 
three methods. 
BIOFILM  
 
METHOD 
Strong biofilm 
formation 
Moderate 
biofilm 
formation 
Weak biofilm 
formation 
Tube method 3 5 8 
Microtitre plate 
method  
8 2 6 
Congo red agar 
method 
8 3 5 
 
      Biofilm formation was considered to be similar between the microtitre 
plate method and congo red agar method while the tube method results vary 
with other two methods.This potential was correlated with the antimicrobial 
resistance of the organism. 
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Table 25: Correlation betweenantimicrobial resistance and  biofilm 
formation 
Antimicrobial resistance No.of Biofilm producers (%) 
Extended Spectrum beta lactamase  
production in Enterobacteriaceae 
(n=5) 
3 (60) 
Methicillin Resistance in 
Staphylococcus (n=2) 
2 (100) 
 
Chart 11: Correlation between antimicrobial resistance  
and  biofilm formation 
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DISCUSSION 
Intravenous catheter use poses an increased risk for blood stream 
infection of which Central venous catheter use stands out as the cause for the 
most dreadful hospital acquired infection in the intensive care units.The 
patients are at risk for acquiring the infection right from the admission of the 
patient in the ICU where the patients are exposed to the nosocomial pathogens 
and throughout the treatment process which is influenced by the hand hygiene 
practices of the hospital staff and the level of aseptic practices taken for CVC 
infusion. Hence my study was aimed to isolate and identify the 
microorganisms causing central venous catheter related blood stream infection 
along with their antimicrobial susceptibility pattern, to analyse the biofilm 
forming potential of the organisms isolated and to correlate the antimicrobial 
resistance with the biofilm formation. The data generated from the results of 
the study were analysed using SPSS version 21 software. 
            In this study including 105 patients from Intensive care units, 66% 
were males and 34% were females.The mean age  in this study was 
46.94.Similarily in a study conducted by Parameswaran et al in Karnataka, 
66.3% males and 33.7% of females were included.[42] Similar results were also 
obtained from a study conducted by HarshaV.Patil et al in Maharastra where 
59.25% were males and 40.74% were females.[56] 
In my study,19% of the patients in the age group of 18-29 years, 12% 
of patients inthe age group of 30-39 years, 19% of patients inthe age group of 
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40-49 years, 32% of patients in the age group of 50-59 years, 6% of the 
patients in the age group of 60-69 years and 12% of the patients in the age 
group of 70-80 years developed CRBSI. 
          This study included only the Central Venous Catheters with three 
lumen. Maria Guembe et al at Spain performed a retrospective study in 
patients with microbiologically proven CRBSI in which all available catheter 
lumens were used to draw blood culture samples and studied 171 episodes of 
proven CRBSI in 154 patients.[57] 
Out of 105 patients with clinical features of CRBSI in this study, 16 
patients had laboratory confirmed CRBSI(15.23%) and the colonizer infection 
rate was 39.04%. 
As with regards to the indication for CVC insertion in this study, the 
patients  subjected to emergency mode of CVC insertion were 64% and those 
subjected to elective mode of CVC insertion were 36% which is statistically 
significant(p=0.006). The mode of insertion whether emergency or elective 
was decided by the clinical status of the patient at the time of admission. In 
this study, lack of peripheral venous access contributed to 26% of CVC 
insertion followed by Total Parenteral Nutrition and Blood transfusion 22%, 
Fluid replacement during surgery 19%, to resuscitate the patient from shock 
16%, CVP monitoring 12% and dialysis 6%. 
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In this study, CRBSI rate was highest with femoral site insertion 
(17.39%),followed by jugular site insertion(16.67%) andsubclavian site 
insertion(13.46%).In a study conducted by Parameswaran et al in Karnataka, 
33.3% of infections were caused by Femoral venous catheters, jugular venous 
catheters were responsible in 23% and subclavian catheters in 21.3%.[42] 
There was significant statistical difference between the incidence and 
infection rates in patients with ≤ 7 days of catheterization when compared with 
the incidence and infection rates in patients with > 7 days of catheterization 
(p= 0.004)Incidence of CRBSI in patients with ≤ 7 days of catheterization in 
all three intensive care units was 7.84% 
Incidence of CRBSI in patients with >7 days of catheterization in all 
three intensive care units was 22.22% 
Infection rate per 1000 device days in patients with ≤ 7 days of 
catheterization in all three intensive care units was 11.11 per 1000 device 
days 
Infection rate per 1000 device days in patients with > 7 days of 
catheterization in all three intensive care units was 15.66 per 1000 device 
days 
In a study conducted by Harsha V.Patil et al in Maharastra, the 
infection rate of CRBSI was 47.31 per 1000 catheter days.[56] 
 78   
 
Whereas the infection rate of CRBSI was very low 2.79 per 1000 
catheter days in a study conducted by Randeep Kaur et al in Kerela.[59]In a 
study conducted by F.J.Mansur et al at Bangladesh, the infection rate of 
CRBSI  was 16%.[61] In a study conducted by K.Chopdekar et al in Mumbai, 
average CRBSI rate was 9.26 per 1000 catheter days ranging from 8.64 per 
1000 catheter days in PICU to maximum rate of 27.02 per 1000 catheter days 
in NICU.[58] In a study conducted by Min Chen et al at China, the catheter 
infection rate was 10.79% and CRBSI occurred 3.05 times per day per 1000 
catheters.[62] 
Among the isolates, Gram negative organisms accounted for 63%, 
Gram positive organisms for 31% and Candida albicans accounted for 6%.In a 
study conducted by Harsha V.Patil in Maharastra, Staphylococcus epidermidis 
was the commonest organism(50%). [56] 
Of the Gram negative organisms, Pseudomonas aeruginosa (25%) was 
the commonest followed by Klebsiellapneumoniae (19%), 
Acinetobacterbaumanii (13%), Klebsiellaoxytoca(6%) and Proteus  
vulgaris (6%).  
Of the Gram positive organisms, Staphylococcus aureus(19%) was the 
commonest followed by Staphylococcus epidermidis (6%) .  
In a study conducted by Parameswaran et al in Karnataka, 64% of the 
CRBSI causing pathogens were Gram positive( commonly Staphylococcus 
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aureus) and 36% were Gram negative. Candida accounted for 10% of 
CRBSI.[42]A study conducted by Banda VenkataRamana et al in Andra 
Pradesh showed similar results to this study.The most common organism was 
Pseudomonas (30%), Klebsiellapneumoniae (18%), E.coli(16%), other 
Enterobacteriaceae(25%) and Non fermentative Gram Negative 
Bacilli(11%).[60]In a study conducted by F.J.Mansur et al at Bangladesh, most 
common pathogens were Pseudomonas sp (23.7%), Acinetobacter sp. 
(18.4%),Staphylococcus aureus(13.2%) and Enterobacteriaceae(10.5%). [61]  In 
a study conducted by Stori et al in Brazil, 61.6% of infections were caused by 
gram positive organisms, 36.5% by gram negative organisms 9% by Candida 
species. [47]In a study conducted by Min Chen et al at China, 46.94% of gram 
negative bacilli and 40.14% of Gram positive cocci and 12.92% of Candida 
strains were isolated. [62]The varied bacterial profile and their incidence in 
CRBSI could be explained by the difference in the pattern of the nosocomial 
pathogens in each healthcare facility. 
 Analysis of Antimicrobial susceptibility showed that 75% of the 
Pseudomonas aeruginosaisolates were sensitive for Amikacin whereas only 
25% of the isolates were sensitive each for Gentamicin, Ciprofloxacin and 
Ceftazidime. 100% of the isolates were sensitive for Imipenem and 
Piperacillin Tazobactum. This is similar to the study conducted by Banda 
Venkata Ramana et al in Andra Pradesh in which only 31% of isolates were 
sensitive to Ceftazidime.[60] 
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  Among Klebsiellapneumoniae ,66% were sensitive to Amikacin and 
Piperacillintazobactum and all the isolates (100%) were sensitive to Imipenem. 
Only 33% of the isolates were sensitive each to Gentamicin, Ciprofloxacin, 
Cotrimoxazole and tetracyclines. 
Among Klebsiella oxytoca,100% of the isolates were sensitive to 
Amikacin, Gentamicin, Tetracycline, Imipenem and Piperacillintazobactum 
whereas none of them were sensitive to ciprofloxacin and cotrimoxazole. All 
the Klebsiella (K.oxytoca and K.pneumoniae) isolates were resistant to 
Cefotaxime. 
Among Acinetobacterbaumanii, 50%were sensitive to Amikacin and 
Tetracycline whereas 100% were sensitive to Cotrimoxazole, Imipenem and 
Piperacillintazobactum. All the isolates were resistant to Gentamicin , 
ciprofloxacin and ceftazidime. 
Among Proteus vulgaris100% were sensitive for Amikacin, 
Tetracycline, Imipenem and Piperacillintazobactum whereas all of them were 
resistant to Gentamicin, Ciprofloxacin, Cotrimoxazole and Cefotaxime. 
    All the Enterobacteriaceaeisolates (100%) were ESBL producers. In 
a study conducted by Mansur et al at Bangladesh, rate of isolation of MRSA, 
Imipenem resistant Pseudomonas sp and ESBL producing Enterobacteriaceae 
were 60%, 44% and 100% respectively.[61] In a study conducted by 
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Parameswaran et al in Karnataka, 6.3% ESBL producers and 30.2% were 
Multidrug resistant organisms .[42] 
Among the Staphylococcus aureus isolates,66% of the isolates were 
Methicillin resistant .In a study conducted by Parameswaran et al in 
Karnataka, 31% of MRSA were isolated.[42]A study conducted by Banda 
VenkataRamana et al in Andra Pradesh showed 65% of MRSA.[60]100% of the 
Methicillin sensitive Staphylococcus aureus isolates were sensitive to 
Amikacin, ciprofloxacin, tetracycline, cotrimoxazole and gentamicin whereas 
all were resistant to penicillin and erythromycin.100% of the Methicillin 
resistant Staphylococcus aureusisolates were sensitive to Amikacin whereas 
only 50% of the isolates were sensitive to erythromycin, cotrimoxazole, 
tetracycline, ciprofloxacin and gentamicin.100% of the Methicillin sensitive 
Staphylococcus epidermidisisolates were sensitive to Amikacin, 
Ciprofloxacin, cotrimoxazole and tetracycline whereas all the isolates were 
resistant to penicillin, erythromycin and gentamicin. 100% of Candida 
albicans were susceptible to fluconazole and voriconazole. 
 
Regarding biofilm formation, the organisms tested for biofilm 
formation were Pseudomonas aeruginosa, Klebsiellapneumoniae, 
Klebsiellaoxytoca, Proteus vulgaris, Acinetobacterbaumanii, Staphylococcus 
aureus, Staphylococcus epidermidis and Candida albicans.  In this study, 
among the gram negative organisms, 73% were biofilm producers and among 
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Gram positive organisms, 50% were biofilm producers. Biofilm production 
was demonstrated by tube method as Strong 18.75%, Moderate 25% and 
Weak 56.25% as compared with Microtitre plate method , in which 43.75%, 
18.75% and 37.5% were Strong, Moderate and Weak respectively and also in 
Congo red agar method,50%, 12.5% and 37.5% were Strong, Moderate and 
Weak respectively. 
Among the ESBL producers, 60% were biofilm producers and among 
the MRSA, 100%  strong were biofilm producers suggesting a strong 
correlation (p=0.04) of biofilm production as a virulence factor in 
antimicrobial resistance. 
 Out of 16 patients with laboratory confirmed CRBSI, 14 patients 
recovered while 2 patients succumbed. The CRBSI mortality rate in my study 
is 12.5%, the infection rate of CRBSI is 14.2 per 1000 catheter days and 
CRBSI incidence is 15.23%. 
 
  
 SUMMARY 
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SUMMARY 
The present study, ―A STUDY ON BIOFILM FORMATION IN 
ORGANISMS CAUSING CENTRAL VENOUS CATHETER 
ASSOCIATED BLOOD STREAM INFECTIONS IN INTENSIVE CARE 
UNIT PATIENTS IN A TERTIARY CARE HOSPITAL - was conducted at 
the Institute of Microbiology, Madras Medical College, RGGGH, Chennai-03. 
It was a prospective study conducted for a period of one year from 
October 2014 to August 2015. The study included 105 patients from Intensive 
Medical, Surgical and Trauma care units with indwelling central venous 
catheter who developed symptoms of blood stream infections after 48hrs of 
catheterization.  
Catheter segment (5cm tip) and peripheral and central venous blood 
samples were collected following aseptic precautions in clinically suspected 
patients with CRBSI and processed by standard microbiological methods 
forisolation, identification, biofilm formation and antimicrobial susceptibility 
testing of the isolates. 
· Out of 105 clinically suspected patients, 16 patients had laboratory 
confirmed CRBSI(15.23%). 
· Most common age group with CRBSI was between 50-59yrs 
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· Most common site of catheter insertion causing CRBSI was femoral 
site (17.39%)  
· CRBSI was common with emergency mode of insertion (81.25%) 
· Out of 16 patients with laboratory confirmed CRBSI,  14 patients 
recovered while 2 patients died. Thus the CRBSI mortality rate is 
12.5% , the infection rate of CRBSI was 14.2 per 1000 catheter days 
and CRBSI incidence is 15.3%.  
·  In this study, 16 isolates were obtained for CRBSI in which Gram 
negative organisms accounted for 63% , Gram positive organisms 
accounted for 31% and Candida species accounted for 6%. Of the 
Gram negative organisms, Pseudomonas aeruginosa was the 
commonest 25% followed by Klebsiella pneumonia 19%, 
Acinetobacterbaumanii 13%, Klebsiellaoxytoca 6% and Proteus 
vulgaris 6%. Of the Gram positive organisms, Staphylococcus 
aureus was the commonest 19% followed by Staphylococcus 
epidermidis 6% . Candida albicans contributed to 6% of CRBSI. 
· All the gram negative isolates were sensitive to Imipenem and all 
the Gram positive isolates obtained were sensitive to Vancomycin. 
· Biofilm production was demonstrated by tube method as Strong 
18.75%, Moderate 25% and Weak 56.25% as compared with 
Microtitre plate method , in which 43.75%, 18.75% and 37.5% were 
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Strong, Moderate and Weak respectively and also in Congo red agar 
method,50%, 12.5% and 37.5% were Strong, Moderate and Weak 
respectively. 
· In this study, among the gram negative organisms, 73% were 
biofilm producers and among Gram positive organisms, 50% were 
biofilm producers. 
· 100% of the Enterobacteraceae isolates were ESBL producers.66% 
of the isolates were Methicillin resistant Staphylococcus aureus. 
· Among the ESBL producers,60% were biofilm producers. Among 
the MRSA, 100% were biofilm producers. 
  
 CONCLUSION 
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CONCLUSION 
Central venous catheters have unquestionable benefits in current 
medical practice, but their potential complications are also well known. One of 
the main complications is catheterrelated bloodstream infection (CRBSI). 
Occurrence of these infections in a hospital set up leads to decrease in the 
quality of health care provided to the patients. These infections often result in 
prolonged hospital stay, thereby exposing the patients to the risks of acquiring 
multiple infections which in turn leads to increase in morbidity as well as 
mortality.  
The present study aimed at diagnosing such infections and identifying 
the potential pathogens implicated, in order to provide better patient care and 
to prevent such infections from occurring in the future.  
The CRBSI rates in this study are slightly on the higher side when 
compared to other studies from India and however the incidence density is 
significantly on the higher side when compared with foreign studies, 
indicating the need for more stringent catheter care protocol.  
In this study, gram negative organisms are implicated more in the 
causation of CRBSI and are also shown to produce strong biofilms than gram 
positive organisms, suggesting that biofilm formation is crucial in the 
pathogenesis of such infections.  
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The study showed the predominance of common nosocomial 
pathogens, MRSA and   P.aeruginosa in the causation of these infections, 
thereby indicating that occurrence of such infections could be controlled by 
active surveillance strategies. The antibiogram of isolates causing CRBSI and 
those forming biofilm in this study clearly  
indicated the increased resistance pattern to routinely used antibiotics 
among these isolates and that irrational usage of antibiotics have paved way 
for such rising resistance trends with biofilms accentuating the transfer of 
resistance genes from one organism to another. The antibiotic resistance 
pattern of the isolates in this study also suggested that Imipenem and 
Vancomycin are excellent drugs to combat infections and are still efficient in 
treating infections, even with those capable of producing biofilm and causing 
bloodstream infections in critical care setting. 
The study concluded that CRBSI are on the rise due to increased 
interventions, and that they are caused by common nosocomial pathogens 
which are still sensitive to reserve drugs and to very few routine drugs, and 
that such infections can be controlled and prevented if strict catheter care 
techniques, rational use of available antibiotics and robust surveillance 
measures are followed. 
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APPENDIX  
  
 APPENDIX I 
LIST OF ABBREVIATIONS 
ATCC – American Type Culture Collection  
ALT – Antibiotic Lock Therapy  
BHI – Brain-Heart Infusion  
BSI – Blood Stream Infection  
CRBSI – Catheter Related Blood Stream Infection  
CDC – Center for Disease Control and Prevention  
CLABSI – Central Line Associated Blood Stream Infection  
CVC – Central Venous Catheter  
CLSI – Clinical Laboratory Standards Institute  
CONS – Coagulase Negative Staphylococci  
CFU – Colony Forming Units  
ELT – Ethanol Lock Therapy  
EPS – Extracellular Polymeric Substance  
HICPAC – Healthcare Infection Control Practices Advisory Committee  
HAI – Hospital Acquired Infection  
IDSA – Infectious Diseases Society of America   
ICU – Intensive Care Unit  
IVC – Intravenous Catheter  
LCBI – Laboratory Confirmed Bloodstream Infection  
MRSA – Methicillin ResistantStaphylococcus aureus 
 MSSA – Methicillin SensitiveStaphylococcus aureus  
MR- Methyl Red test  
ml – Millilitre  
µg – Microgram  
MHA -Mueller Hinton Agar  
NHSN – National Health Safety Network  
NICU – Neonatal Intensive Care Unit  
NLF – Non lactose Fermenting  
OF –Oxidation and Fermentation  
PICC – Peripherally Inserted Central Venous Catheter  
Spp –Species  
TPN – Total Parenteral Nutrition  
TSI –Triple Sugar Iron  
VP – VogesProskauer test  
 
  
 APPENDIX  II 
 
A.STAINS AND REAGENTS 
 
I. Gram staining 
Methyl violet (2%)   l0g Methyl violet in l00ml 
absolute alcohol in 1litre of 
distilled water (primary stain) 
Grams Iodine    l0g Iodine in 20g KI 
(fixative) 
Acetone    Decolourising agent 
Carbolfuchsin 1%   Secondary stain 
B.MEDIA USED: 
 
1.MacConkey agar 
Peptone    20g 
Sodium taurocholate  5g 
Distilled Water   1 ltr 
Agar     20g 
2% neutral red in 50% ethanol 3.5ml 
10% lactose solution  l00mI  
Dissolve peptone and taurocholate in water by heating. Add agar and 
dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well 
and mix. Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 
15minutes. 
 
 2. Blood agar (5% sheep blood agar) 
Peptone     l0g 
NaCl      5g 
Distilled water    1 Ltr 
Agar      10g 
       Dissolve ingredients in distilled water by boiling, and add 5% sheep 
blood(sterile) at 55°C adjust pH to 7.4. 
3. Chocolate agar 
Sterile defibrinated blood  10 ml 
Nutrient Agar (melted)  100 ml 
When the temperature was about 75°C, sterile blood was added with 
constant agitation. After addition of blood, kept in water bath and heating was 
continued till the blood changed to chocolate colour. Cooled to about 50° C 
and poured about 15ml into petri dishes with sterile precaution. 
4. Mueller Hinton Agar: 
Beef, infusion   300ml 
Casein acid hydrolysate  17.5g 
Starch      1.5g 
Agar      10g 
Distilled water                                 1 litre 
Final pH (at 25°C) 7.3±0.1 
Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. 
 
 5.TRYPTIC SOY BROTH 
This is reconstituted from the dehydrated form according to the 
manufacturer’s instructions. For adult clinical practice, the reconstituted broth 
is distributed in 20 ml amounts in 30 ml medical flat bottles with perforated 
screw-caps and rubber liners. Autoclave with caps tight at 1210C for 20 
minutes. The exposed area of the liner in the perforation should be covered 
with a foil cap added before autoclaving.  
C.MEDIA AND REAGENTS REQUIRED FOR BIOCHEMICAL 
IDENTIFICATION: 
 
1.Oxidase Reagent 
     Tetra methyl p-phenylenediaminedihyrochloride- 1% aqueous solution. 
2.Catalase test 
3% hydrogen peroxide 
3.Indole test 
Kovac’s reagent 
Amyl or isoamyl alcohol     150ml 
Para dimethyl amino benzaldehyde  10g 
Concentrated hydrochloric acid    50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
4. Christensen’s Urease test medium 
Peptone      1g 
Sodium chloride     5g 
 Dipotassium hydrogen phosphate   2g 
Phenol red      6ml 
Agar       20g 
Distilled water     1 ltr 
10% sterile solution of glucose   l0ml 
Sterile 20% urea solution    l00ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by 
autoclaving in a flask at 121°C for 30min. Cool to about 50°C, add the glucose 
& urea, and tube the medium as slopes. 
5. Simmon’s Citrate Medium 
Koser’s medium     1 ltr 
Agar       20g 
Bromothymol blue     0.2% 40ml 
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
6.Triple Sugar Iron medium 
Beef extract     3g 
Yeast extract    3g 
Peptone     20g 
Glucose     1g 
Lactose    l0g 
Sucrose    l0g 
Ferric citrate     0.3g 
 Sodium chloride   5g 
Sodiumthiosulphate   0.3g 
Agar     12g 
Phenol red 0.2% solution  l2ml 
Distilled water    1 ltr 
Heat to dissolve the solids, add the indicator solution, mix and 
tube.Sterilize at 121°C for 15 min and cool to form slopes with deep butts. 
7.Glucose phosphate broth 
Peptone      5g 
Dipotassium hydrogen phosphate  5g 
Water      1 ltr 
Glucose 10% solution   50ml 
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter 
dispense in 5ml amounts and sterilize at 121°C for 15min. Sterilize the glucose 
solution by filtration and add 0.25ml to each tube 
Methyl Red Reagent 
Methyl Red      10mg 
Ethyl alcohol     30ml 
Distilled water    20ml 
VogesProskauer Reagent 
Reagent A:  
Alpha naphthol   5g 
Ethyl alcohol    100ml 
  
Reagent B:  
Potassium hydroxide   40g 
Distilled water    100ml 
8. Peptone water sugars fermentation test medium. 
To the basal medium of peptone water, add sterilised sugars, 
1%indicator bromothymol blue with Durham’s tube. 
Basal medium peptone water 
Sugar solutions: 
Sugar      1ml 
Dislilled water    l00ml 
pH = 7.6. 
9. Potassium nitrate broth 
Potassium nitrate (KN03)   0.2gm 
Peptone     5.0gm 
Distilled water    100ml 
The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclave. 
10.Decarboxylase media: 
10a.Moeller decarboxylase broth base: 
Ingredients     gms/L 
Peptone    5 
Beef extract    5 
 Bromocresol purple   0.01 
Cresol red    0.005 
Glucose    0.5 
Pyridoxal    0.005 
Final pH 6 
10b. Aminoacid: 
Add 10 g of the levo form of the amino acid for 1000ml.mix and 
dispense in sterile tubes. 
11. Hugh&Leifson’s Oxidation –Fermentation test: 
Peptone     2g 
Sodium chloride     5g 
D-glucose                10g 
Bromothymol blue     0.03g 
Agar       3.0g 
Dipotassium phosphate   0.30g 
Distilled water     1L 
pH =7.1 
Basal medium is autoclaved.1% of sterile sugar solutions is added to 
the basal medium. Dispense into sterile test tubes without slant. 
12. Phenolphthalein diphosphate agar 
Sterilize 1% aqueous solution of sodium phenolphthalein diphosphate 
by filtration and store at 4ºC.Add 10ml of this solution to 1000ml melted 
nutrient agar cooled to 50ºCand pour plates. Grow the staphylococcus 
 overnight at 37ºC on the medium. Invert the plate and pour a few drops of 
ammonia solution SG 0.88 in to the lid. Read as positive a culture whose 
colonies turn bright pink within a few minutes. The colour soon fades. 
 
13.Mannitol motility medium:  
Peptone 20 g  
Mannitol 2 g  
Potassium nitrate 1 g  
Agar 3 g  
Phenol red 0.04 g  
Suspend 26 g of the medium in 1000 ml of distilled water. Heat to 
boiling to dissolve completely. Dispense in tubes and sterilize by autoclaving.  
 
 
APPENDIX  III 
 
Identification Tests used for the Isolates  
GRAM STAINING  
Procedure:  
1. Smear is prepared and heat fixed.  
2. Cover the smear with Gentian violet for 1 minute.  
3. Wash and cover with Gram’s iodine for 1 minute.  
4. Wash and decolorize with acetone for 2 seconds.  
5. Wash and counterstain with dilute carbolfuchsin for 30 seconds.  
6. Wash with water, dry and observe under oil immersion.  
 
MOTILITY BY HANGING DROP PREPARATION  
Procedure:  
1. A hollow ground glass slide with a shallow circular concavity is taken.  
2. The concavity is encircled with soft petroleum jelly with the help of a stick.  
3. A drop of the suspension of the culture is placed on the coverslip.  
4. The slide is then inverted over the coverslip so that the drop hangs into the 
centre of concavity of the slide.  
5. Examine the drop first with low power objective to view the edge of the 
drop and then with the high power to look for motile bacteria.  
 
 
 
 
 
CATALASE TEST  
Principle: This test demonstrates the presence of catalase, the enzyme that 
catalyzes the release of oxygen from hydrogen peroxide.  
Procedure: A small amount of the colony to be tested is picked with a sterile 
thin glass rod and it is inserted into 3% hydrogen peroxide solution held in a 
small, clean tube.  
Interpretation: Productionof gas bubbles was interpreted as positive catalase 
test and no bubble formation was interpreted as negative.   
 
COAGULASE TEST  
Principle: This test demonstrates the presence of enzyme coagulase produced 
by the organism.  
SLIDE COAGULASE TEST  
Procedure: A clean slide was taken and two portions made on it with a glass 
marking pencil. A drop of normal saline was placed on each portion. A portion 
of the colony was taken with the help of a loop and was emulsified in each of 
the two drops. A loopful of undiluted plasma was added to one of the 
suspensions. Clumping was seen if the strain was coagulase positive.  
The control slide should not show any clumping.  
 
  
 
 
TUBE COAGULASE TEST  
To 1.0 ml of 1 in 6 plasma diluted in saline (0.85%), 0.1 ml of broth 
culture of the Staphylococci was added and incubated at 37 °C for 2 4 hours.  
If the test is positive, due to the formation of the coagulum, the fluid 
does not flow when the tube is tilted. If it was negative at the end of 4 hours, it 
was left overnight at room temperature and the reading taken next morning.  
CONTROL: Coagulase positive: Staphylococcus aureus  
Coagulase negative: Staphylococcus epidermidis  
OXIDASE TEST  
Principle: This test demonstrates the presence of cytochrome oxidase enzyme 
which catalyses oxidation of cytochrome by oxygen.   
Reagent: 1% Tetramethyl-p-phenylene-diaminedihydrochloride.  
Procedure: Few drops of the freshly prepared 1% reagent were added to a 
strip of filter paper. A speck of culture was rubbed on it using a sterile glass 
rod.  
Interpretation: A positive reaction was indicated by a dark purple colour 
appearing within  
10 seconds.  
Positive control: Pseudomonas aeruginosa  
Negative control: Escherchia coli  
Gram negative bacilli, both lactose fermenters and non-lactose 
fermenters, were subjected to the following tests.  
A single colony of the organism was inoculated into peptone water and 
incubated for about 2 – 4 hours at 37 °C. Material from this was used for the 
biochemical tests.  
 
 
 
INDOLE PRODUCTION TEST  
Principle: This test demonstrates the presence of enzyme tryptophanase that 
degrades tryptophan to indole.  
Procedure:  
The test organism is inoculated into peptone water and incubated for 24 
hours. 0.5 ml of Kovac’s reagent is added to overnight broth.  
Interpretation: Formation of a pink colour ring indicates a positive test. 
METHYL RED TEST  
Principle: This test detects the production of acid during the fermentation of 
glucose and maintenance of pH below 4.5.  
Procedure: The test organism is inoculated into glucose phosphate medium 
and incubated at  
37 0C for 48 to 72 hours. Few drops of 0.04% solution of methyl red is added 
to the culture.  
Interpretation: Development of red colour is interpreted as a positive test.  
VOGES-PROSKAUER TEST  
Principle: This test detects the production of acetyl methyl carbinol from 
pyruvic acid as an intermediate stage in its conversion to 2,3 butylene glycol. 
In presence of alkali and atmospheric oxygen, small amount of acetyl methyl 
carbinol is oxidized to diacetyl which reacts with peptone in the broth.  
Procedure: The test organism is inoculated into glucose phosphate medium 
and incubated at  
37 °C for 48 to 72 hours. 0.6 ml of 5% solution of alpha-naphthol in ethanol 
and 0.2 ml of 40% KOH is added to 1 ml of culture.  
Interpretation: Development of pink colour within 30 mins is interpreted as a 
positive test.  
 
 
CITRATE UTILISATION TEST:  
Principle: Some bacteria can obtain energy by utilising citrate as the sole 
source of carbon.  
The utilisation of citrate was detected in Simmon’s citrate medium by 
the production of alkaline by products.  
Procedure: The entire surface of the slant was inoculated lightly from a young 
culture and incubated at 37 °C for 24-48 hours.  
Interpretation: The test was considered positive when the medium turned 
deep blue in colour along with growth on the surface.  
Positive Control: Klebsiellapneumoniae 
Negative Control: Escherchia coli  
UREASE TEST:  
Principle: Bacteria possessing urease enzyme hydrolyze urea, producing 
ammonium bicarbonate and CO2 resulting in alkalinisation and increase in pH 
of the medium.  
Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose or urea. Adjust pH to 6.8 – 6.9 and sterilize by 
autoclaving in a flask at 121 °C for 15 minutes. Cool to about 50 °C. Add the 
glucose and the urea solutions and tube the mediumas deep slopes.  
Procedure: The medium was inoculated with the test organisms and incubated 
at 37 °C for 24 – 48 hours.  
Interpretation: Development of pink colour throughout the medium was a 
positive test; yellow colour was a negative test.  
Positive control: Proteus vulgaris  
Negative control: Escherchia coli  
 
 
 
 
MANNITOL MOTILITY TEST  
In semi-solid agar medium, motile bacteria ―swarmǁ and give a diffuse 
spreading growth that is easily recognized by the naked eye. Motility may thus 
be detected more easily than by microscopical ―hanging dropǁ method  
Procedure: The centre of butt of the MMM was stabbed with a straight wire 
charged with a young culture incubated at 37 °C overnight.  
TRIPLE SUGAR IRON AGAR (TSI)  
Principle: This detects the fermentation of the three sugars (namely glucose, 
lactose and sucrose), the production of gas and hydrogen sulphide. Lactose 
and sucrose are present in a concentration ten times that of glucose. Phenol red 
and ferrous sulphate serve as indicators of acidification and H2 S formation, 
respectively.  
Adjust the pH to 7.6. Then add phenol red 0.24 g. Distribute into small 
test tubes in 4ml quantities and autoclave at 121 °C for 15 minutes. Keep the 
tubes in a slanting position immediately after that, so as to get a butt &slan of 
equal proportions.  
Procedure: The centre of butt of the TSI was stabbed with a straight wire 
charged with a young culture and the slant was streaked and incubated at 37 
°C overnight for 18 to 24 hours.  
Interpretation: 
Reaction Explanation 
Acid butt (yellow) 
Alkaline slant (red) 
Glucose fermented 
Acid butt (yellow) 
Acid slant (yellow) 
Glucose and lactose/or sucrose 
fermented 
 
 
Gas bubbles in butt Aerogenic cultures indicate 
production of 
CO2 or H2 
Medium sometimes split, 
blackening in 
butt 
Hydrogen sulphide produced 
Alkaline slant and butt (entire 
medium  
red)   
 
Glucose, lactose and sucrose 
nonutilizers 
 
SUGAR FERMENTATION TESTS:  
The fermentation of individual sugars was tested out separately. Only 
the important sugars were put up namely, glucose, lactose, sucrose.  
Procedure: The sugar solutions were inoculated from the peptone water with 
the help of Pasteur pipette and incubated overnight at 37 °C for upto 7 days. 
The tubes are examined for acid and gas production.  
Interpretation:  
Pink discolouration of medium: Acid production (fermentation of the 
sugar)  
No colour change No fermentation of the sugar  
Gas bubbles in Durham’s tube Gas production  
 
OXIDATION-FERMENTATION TEST (Hugh- Leifson’s method) 
Procedure: Hugh-Leifson’s basal medium is prepared and the carbohydrate to 
be added is sterilized separately and added to give a final concentration of 1%. 
The medium is then stabbed to a depth of about 4 cm.  
 
 
Duplicate tubes of medium are inoculated by stabbing. One tube is 
promptly covered with a layer of sterile melted petroleum jelly to a depth of 5-
10 mm and both are incubated for upto 30 days.  
Interpretation: Fermenting organisms produce an acid reaction throughout 
the medium in covered (anaerobic) as well as the open (aerobic) tube.  
Oxidizing organisms produce an acid reaction only in the open tube.  
Organisms that cannot breakdown the carbohydrate aerobically or 
anaerobically produce an alkaline reaction in the open tube and no change in 
covered tube.  
NITRATE REDUCTION TEST  
Principle: This demonstrates the presence of nitrate reductase enzyme which 
reduces nitrate into nitrite.  
Test organism is incubated in 5ml of nitrate broth for 24 to 48 hours. 
Equal volumes of reagent A and B are mixed just before use. 0.1 ml of the 
reagent mixture is added to the culture.  
Interpretation: Development of red colour within few minutes is considered 
positive.  
AMINOACID DECARBOXYLATION TEST  
Principle: Decarboxylases are a group of substrate-specific enzymes, which 
are capable of reacting with carboxyl portion of amino acids, forming alkaline-
reacting amines, with formation of C02 as a second product.  
 
Add 10g (final concentration – 1%) of L (levo) form of amino acid (lysine, 
ornithine or arginine).  
Dissolve the solids in water and adjust the pHto 6. Add the indicators, mix and 
distributed into four equal portions. To this, add the amino acids to be tested 
except the control tube.  
 
 
Procedure: From a well isolated colony of the test organism, inoculate two 
tubes of Moeller decarboxylase medium, one containing the amino acid to be 
tested, the other to be used as a control tube devoid of amino acid. Overlay 
both tubes with sterile mineral oil to cover about 1cm of the surface and 
incubate at 370 C for 18-24 hours.  
Interpretation: The medium first becomes yellow due to acid production 
from glucose fermentation; later, if decarboxylation occurs, the medium 
becomes purple. The control tube remains yellow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ANNEXURES  
 
 
 
 
 
 
 
 
 
PROFORMA 
• Name 
• Age/Sex 
• Adress 
• Occupation 
• Date of Admission 
• I.P.no: 
• Provisional Diagnosis 
• Presenting complaints 
• Past History 
• Personal History 
• General Examination 
• Systemic Examination 
• Invesigations done 
• Systemic Antibiotics given 
• Details about Catheterisation 
 
v Date of catheterisation 
v Indication 
v Type of placement: emergency/elective 
v No.of attempts to place the catheter 
v Type of catheter used 
v Site&side of insertion 
v Length of catheter inside the patient 
v Complications during insertion 
v Frequency of catheter manipulation 
v Duration of catheterization 
v Cause of catheter removal 
v Fever after removal 
v Length of time in ICU 
 
  
 
 
Microbiological investigation: 
Sample collected: 
• Swab from exit site 
• Catheter tip 
• Catheter Blood sample 
• Peripheral Blood sample 
Isolates obtained : 
-Catheter tip: 1) Maki’s roll plate 
2)Brun Buisson’s method 
-Catheter blood sample: 
-Peripheral blood sample: 
Antimicrobial susceptibility pattern: 
Biofilm detected: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
TITLE OF THE STUDY :“A study on Biofilm formation in organisms 
causing Central Venous Catheter related blood stream infections in 
intensive care unit patients in a tertiary care hospital” 
 
Name :     Date : 
Age :     OP No  :  
Sex :     Project Patient No : 
 
Documentation of the informed consent 
I _____________________________ have read the information in this 
form (or it has been read to me). I was free to ask any questions and they have 
been answered. I hereby give my consent to be included as a participant in “A 
study on Biofilm formation in organisms causing Central Venous 
Catheter related blood stream infections in intensive care unit patients in 
a tertiary care hospital’’ 
I have read and understood this consent form and the information 
provided to me. 
0I have had the consent document explained to me. 
1. I have been explained about the nature of the study. 
2. I have been explained about my rights and responsibilities by the 
investigator.  
3. I have informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) 
treatment. 
 
 
4. I have been advised about the risks associated with my participation in this 
study. 
5. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms. 
6. I have not participated in any research study within the past ________ 
month(s). 
7. I am aware of the fact that I can opt out of the study at any time without 
having to give my reason and this will not affect my future treatment in this 
hospital. 
8. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without any consent. 
9. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
10. I have understood that my identity will be kept confidential if my data are 
publicly presented. 
11. I have had my questions answered to my satisfaction. 
12. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact 
the investigator. By signing this consent form I attest that the information 
given in this document has been clearly explained to me and understood by 
me, I will be given a copy of this consent document. 
  
 
 
For participants: 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent/For age 10-17 yrs-Name& signature 
of the parent/guardian.) 
Name ___________________________________ 
Signature_________________________ 
Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name ___________________________________ 
Signature_________________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
 
Name ___________________________________ 
Signature_________________________ 
Date_______________ 
 
MASTER CHART 
  
 
 
KEY TO MASTER CHART 
 
Duration of catheterization 
1 - ≤7 days 
2 - >7 days 
 
Indication for catheterization 
 
A-Fluid replacement during surgery 
B-To resuscitate the patient from shock 
C-Lack of peripheral venous access 
D-Blood transfusion and Total parenteral nutrition 
E-Central Venous Pressure monitoring 
F-Dialysis 
 
Duration of ICU stay 
1- ≤1week 
2- 1 to 2 weeks 
3- 2 to 3 weeks 
4- 3 to ≥ 4 weeks 
5-  
Sample Category  
Category[1]- Patients with suspected CRBSI with maintenance Central venous 
catheterization. 
Category[2]- Patients with suspected CRBSI in whom maintenance 
catheterization is not indicated and central venous catheter can be removed 
Category[3]- For patients with difficult peripheral vein access.  
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1 48 /M SICU 2 B EMERGE RT.SUBCLAVIAN 1 2 HOLLOW VISCOUS 
PERFORATION
1
2 55/m IMCU 1 D ELECTIV
E
RT.JUGULAR 1 2 MYASTHENIA GRAVIS 1
3 28/F IMCU 2 F ELECTIV
E
LT.JUGULAR 2 2 APLASTIC ANEMIA 2
4 43/M IMCU 1 F EMERGE
NCY
LT.SUBCLAVIAN 1 3 ACUTE PANCREATITIS 1
5 40/M IMCU 3 D EMERGE
NCY
RT.FEMORAL 2 2 GBS 2
6 55/M SICU 1 B EMERGE
NCY
LT.SUBCLAVIAN 1 3 RTA BLUNT INJURT 
ABDOMEN
1 ACINETOBACTER 
BAUMANII
R R R R R S R S S M ST ST SUCCUM
BED
7 35/M ITCU 4 F EMERGE
NCY
RT.SUBCLAVIAN 1 2 HEAD INJURY 2
8 38/M SICU 1 F EMERGE
NCY
RT.SUBCLAVIAN 1 3 ACUTE PANCREATITIS 1
9 68/F IMCU 2 C EMERGE
NCY
LT.FEMORAL 2 3 CVA 3
10 58/F SICU 1 A ELECTIV
E
RT.JUGULAR 1 2 CA BREAST 1
11 52/M IMCU 4 C EMERGE
NCY
RT.FEMORAL 2 3 COPD/TYPE 2 RENAL 
FAILURE
3 PSEUDOMONAS 
AERUGINOSA
S S S S S S S W M W RECOVER
ED
12 32/M IMCU 4 D EMERGE
NCY
LT.SUBCLAVIAN 2 3 HANGING/HEAD INJURY 1
13 46/M ITCU 3 B EMERGE
NCY
SUBCLAVIAN 2 3 RTA POLYTRAUMA 2 .
14 36/M SICU 2 B EMERGE
NCY
JUGULAR 2 2 SELF FALL POPLITEAL 
VEIN INJURY
1
15 29/F IMCU 2 C ELECTIV
E
SUBCLAVIAN 1 2 POST NATAL PPH /ARF 3
16 67/F SICU 1 A ELECTIV
E
SUBCLAVIAN 1 2 INTESTINAL 
OBSTRUCTION
1
17 28/F IMCU 3 D ELECTIV
E
RT.SUBCLAVIAN 2 4 OPC POISONING 2 KLEBSIELLA 
PNEUMONIAE
S S R R S S S R(ES
BL)
S(ES
BL)
ST ST ST RECOVER
ED
18 48/F SICU 1 A ELECTIV
E
JUGULAR 1 2 MNG 1
19 22/M SICU 2 F ELECTIV
E
LT.FEMORAL 1 3 CHONDROMYXOID 
FIBROMA
2
20 35/M IMCU 2 F EMERGE
NCY
SUBCLAVIAN 2 2 APLASTIC ANEMIA 1
21 49/M ITCU 4 C EMERGE
NCY
JUGULAR 1 2 HEAD INJURY 3
22 55/M ITCU 3 B EMERGE
NCY
RT.FEMORAL 2 3 RTA POLYTRAUMA 1
23 58/M ITCU 2 B EMERGE
NCY
LT.JUGULAR 2 2 POLYTRAUMA 
VASCULAR INJURY
3 STAPHYLOCOCCUS 
AUREUS
S S R S S R S W W W RECOVER
ED
24 25/F IMCU 2 C EMERGE
NCY
SUBCLAVIAN 1 3 POST LSCS/ AKI 3
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25 45/M SICU 1 F ELECTIV
E
JUGULAR 1 2 RCC 2
26 53/M SICU 2 B EMERGE
NCY
SUBCLAVIAN 2 3 ILEAL PERFORATION 1
27 29/M ITCU 3 D EMERGE
NCY
JUGULAR 2 2 SOL 
HYDROCEPHALUS/SHUN
2
28 26/F IMCU 4 D EMERGE
NCY
LT.FEMORAL 2 3 RESPIRATORY FAILURE 2
29 34/M SICU 2 A ELECTIV
E
SUBCLAVIAN 1 2 POST APPENDECTOMY 
WITH INTESTINAL 
1
30 20/F IMCU 3 F EMERGE
NCY
RT.JUGULAR 2 2 ACUTE INTERMITTENT 
PORPHYRIA
1 PSEUDOMONAS 
AERUGINOSA
R R R R S S S W W W RECOVER
ED
31 36/F SICU 1 A ELECTIV
E
SUBCLAVIAN 1 2 POST 
CHOLECYSTECTOMY
1
32 49/F SICU 1 A ELECTIV
E
LT.FEMORAL 1 2 INCISIONAL HERNIA 2
33 50/F IMCU 3 C EMERGE
NCY
RT.FEMORAL 2 2 AORTIC DISSECTION 3
34 51/M IMCU 2 D EMERGE
NCY
RT.SUBCLAVIAN 1 2 DCLD/HEPATIC 
ENCEPHALO[ATHY GR 2
1 KLEBSIELLA 
OXYTOCA
S S R R S S S R S(ES
BL)
M S S RECOVER
ED
35 66/M SICU 3 F ELECTIV
E
JUGULAR 2 3 INTESTINAL 
OBSTRUCTION
1
36 45/M ITCU 4 B EMERGE
NCY
SUBCLAVIAN 1 2 RTA POLYTRAUMA 2
37 52/F SICU 2 C ELECTIV
E
SUBCLAVIAN 2 3 CA BREAST 3
38 43/M IMCU 3 D EMERGE
NCY
RT.FEMORAL 2 2 GBS 1
39 39/M SICU 3 B EMERGE
NCY
JUGULAR 2 3 SMALL BOWEL 
GANGRENE
2
40 27/M IMCU 4 F EMERGE
NCY
RT.FEMORAL 2 4 ACUTE MENINGO 
ENCEPHALITIS
2 PROTEUS VULGARIS S R R R S S S R (ESB
L)
N W W RECOVER
ED
41 35/M ITCU 3 A EMERGE
NCY
SUBCLAVIAN 1 3 HEAD INJURY 1
42 48/F SICU 2 F ELECTIV
E
JUGULAR 1 3 CA CERVIX 1
43 72/F IMCU 2 F ELECTIV
E
SUBCLAVIAN 1 2 CVA 1
44 70/M SICU 3 C EMERGE
NCY
JUGULAR 2 3 CA RECTUM 3
45 35/M SICU 1 A EMERGE
NCY
SUBCLAVIAN 1 2 SIGMOID VOLVULUS 2
46 74/M ITCU 3 C ELECTIV
E
RT.JUGULAR 2 2 SELF FALL HEAD INJUR 2 PSEUDOMONAS 
AERUGINOSA
S R R R R S S ST ST ST SUCCUM
BED
47 56/M SICU 1 C ELECTIV
E
SUBCLAVIAN 1 2 HODGKINS DISEASE 3
48 35/F SICU 2 A ELECTIV
E
LT.FEMORAL 1 3 EMPYEMA GB 1
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49 65/F IMCU 1 D EMERGE
NCY
SUBCLAVIAN 1 3 HEPATIC 
ENCEPHALOPATHY
2
50 29/M IMCU 2 E EMERGE
NCY
JUGULAR 2 3 SNAKE BITE 1
51 69/M SICU 2 C ELECTIV
E
RT.FEMORAL 1 3 MALIGNANT 
OBSTRUCTIVE JAUNDICE
3
52 56/M ITCU 3 B EMERGE
NCY
SUBCLAVIAN 2 3 RTA POLYTRAUMA 1
53 45/F ITCU 4 F EMERGE
NCY
RT.SUBCLAVIAN 2 3 RTA POLYTRAUMA 1 STAPHYLOCOCCUS 
AUREUS
S R S R R S R MRS
A
M ST ST RECOVER
ED
54 26/M IMCU 1 C EMERGE
NCY
JUGULAR 1 3 PARAQUAT POISONING 3
55 49/F SICU 1 A ELECTIV
E
SUBCLAVIAN 1 3 CA TONGUE 1
56 36/F ITCU 2 C EMERGE
NCY
LT.FEMORAL 1 2 RT. CEREBELLAR SOL / 
HYDROCEPH
3
57 48/M ITCU 3 B EMERGE
NCY
JUGULAR 2 3 RTA POLYTRAUMA 2
58 65/M SICU 2 F ELECTIV
E
SUBCLAVIAN 1 2 INTESTINAL 
OBSTRUCTION
1
59 55/M SICU 2 F EMERGE
NCY
RT.SUBCLAVIAN 2 3 INTESTINAL 
OBSTRUCTION
1 KLEBSIELLA 
PNEUMONIAE
S R S S S S R(ES
BL)
S(ES
BL)
M ST ST RECOVER
ED
60 45/M IMCU 1 D ELECTIV
E
SUBCLAVIAN 1 2 HODGKINS DISEASE 2
61 37/F IMCU 2 E ELECTIV
E
SUBCLAVIAN 2 2 SLE/CKD 1
62 38/M ITCU 3 C EMERGE
NCY
FEMORAL 2 3 RTA POLYTRAUMA 3
63 46/F SICU 2 A ELECTIV
E
JUGULAR 1 2 SPLENECTOMY 2
64 74/M IMCU 2 B EMERGENCY LT.JUGULAR 2 2 SHT/CVA/MODS 1
STAPHYLOCOCCUS 
EPIDERMIDIS S R S R S S R S
NEG
ATI
VE
W W RECOVERED
65 59/M SICU 3 A EMERGE
NCY
SUBCLAVIAN 2 3 SMALL BOWEL 
GANGRENE
1
66 32/M ITCU 4 C EMERGE
NCY
JUGULAR 1 2 RTA HEAD INJURY 3
67 29/M IMCU 3 F EMERGE
NCY
FEMORAL 1 3 ACUTE MENINGO 
ENCEPHALITIS
1
68 46/M SICU 2 B EMERGE
NCY
SUBCLAVIAN 2 3 RTA BLUNT INJURT 
ABDOMEN
1
69 52/F SICU 2 A ELECTIV
E
SUBCLAVIAN 2 2 CA BREAST 2
70 21/F IMCU 4 C ELECTIV
E
FEMORAL 2 2 KRABBE 
LEUKODYSTROPHY
3
71 62/M SICU 1 A EMERGE
NCY
RT.SUBCLAVIAN 2 3 HOLLOW VISCOUS 
PERFORATION
1 ACINETOBACTER 
BAUMANII
S R R R S S S S S M S S RECOVER
ED
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72 59/M ITCU 3 B EMERGE
NCY
SUBCLAVIAN 2 2 RTA POLYTRAUMA 2
73 54/F SICU 1 A ELECTIV
E
JUGULAR 1 2 MNG 1
74 60/M SICU 1 D EMERGE
NCY
SUBCLAVIAN 1 2 MALIGNANT 
OBSTRUCTIVE JAUNDICE
2
75 65/M IMCU 1 D EMERGE
NCY
FEMORAL 1 3 COPD/ COR PULMONALE 2
76 59/M IMCU 2 C EMERGE
NCY
JUGULAR 2 2 SLEEP APNEA /RESP. 
FAILURE
3
77 66/F ITCU 3 F ELECTIV
E
SUBCLAVIAN 2 2 SELF FALL HEAD INJUR 1
78 45/M SICU 2 C EMERGE
NCY
SUBCLAVIAN 2 3 HOLLOW VISCOUS 
PERFORATION
3
79 48/F ITCU 3 C EMERGE
NCY
JUGULAR 2 2 CRUSH INJURY BOTH 
LIMBS
3
80 39/M SICU 1 A EMERGE
NCY
RT.FEMORAL 1 3 HOLLOW VISCOUS 
PERFORATION
1 KLEBSIELLA 
PNEUMONIAE
R R R R S R R S(ES
BL)
W R M RECOVER
ED
81 29/M IMCU 2 D EMERGE
NCY
SUBCLAVIAN 1 3 OPC POISONING 2
82 33/M IMCU 2 E EMERGE
NCY
SUBCLAVIAN 2 2 SNAKE BITE 2
83 21/F SICU 1 A ELECTIV
E
JUGULAR 1 3 SLE/VULVAL 
ULCERATION
1
84 23/M ITCU 3 F ELECTIV
E
FEMORAL 1 2 RT CEREBRAL SOL 2
85 34/F SICU 1 B EMERGE
NCY
SUBCLAVIAN 1 3 APPENDICULAR 
PERFORATION
1
86 42/M SICU 1 C EMERGE
NCY
FEMORAL 1 2 HOLLOW VISCOUS 
PERFORATION
3
87 45/M ITCU 2 C EMERGE
NCY
RT.FEMORAL 1 2 RTA HEAD INJURY 3 CANDIDA ALBICANS S N W W RECOVER
ED
88 58/M ITCU 4 F ELECTIV
E
SUBCLAVIAN 2 2 SOL 
HYDROCEPHALUS/SHUN
2
89 48/M SICU 3 C EMERGE
NCY
SUBCLAVIAN 2 3 STAB INJURY ABDOMEN 3
90 26/F IMCU 1 E EMERGE
NCY
SUBCLAVIAN 1 2 POST LSCS/ AKI 1
91 72/M IMCU 1 F ELECTIV
E
FEMORAL 1 2 CVA 2
92 66/M SICU 2 A EMERGE
NCY
SUBCLAVIAN 2 3 SPLENECTOMY 2
93 73/F ITCU 2 C EMERGE
NCY
JUGULAR 1 2 SELF FALL 3
94 49/M ITCU 4 F EMERGE
NCY
SUBCLAVIAN 2 2 ICSOL/ HYDROCEPHALUS 2
95 36/M SICU 2 C EMERGE
NCY
LT.JUGULAR 2 3 ILEAL PERFORATION 2 STAPHYLOCOCCUS 
AUREUS
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96 42/M SICU 3 B EMERGE
NCY
SUBCLAVIAN 2 2 ILEAL PERFORATION 2
97 35/F ITCU 3 F EMERGE
NCY
FEMORAL 2 2 HEAD INJURY 1
98 49/M ITCU 4 C EMERGE
NCY
SUBCLAVIAN 1 2 RTA POLYTRAUMA 3
99 68/M SICU 1 A ELECTIV
E
SUBCLAVIAN 1 3 INTESTINAL 
OBSTRUCTION
2
100 35/F IMCU 1 C ELECTIV
E
FEMORAL 1 2 HYPOTHYROIDISM/ANAS
ARCA
3
101 38/F IMCU 3 E ELECTIV
E
SUBCLAVIAN 2 2 SLE/ LUPUS NEPHRITIS 1
102 75/M SICU 2 F ELECTIV
E
JUGULAR 2 2 CA RECTUM 2
103 40/M SICU 3 A ELECTIV
E
RT.SUBCLAVIAN 2 2 INTESTINAL 
OBSTRUCTION
2 PSEUDOMONAS 
AERUGINOSA
S R R R R S S W M M RECOVER
ED
104 46/M SICU 2 B EMERGE
NCY
JUGULAR 2 3 HOLLOW VISCOUS 
PERFORATION
2
105 33/F IMCU 2 C EMERGE
NCY
SUBCLAVIAN 2 3 GDM/HYPOKALEMIA 3
